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Osteoarthritis in China and the USA: A Comparison of
Prevalence and Risk Factors
MC Nevitt, DT Felson, Y Zhang, L Lui, W Yu, L Xu.
U. California,San Francisco,BostonU, Peking Union Medical
College
Background: Racial and geographic differences in the occurrence
of disease have important public health implications and can
provide clues about disease etiology. Little is known of the com-
parative prevalence of osteoarthritis (OA), although some studies
have suggested low rates of hip OA in China. China, with its
burgeoning elderly population will have an estimated 210 million
people aged 65 and over by 2027. It is not known whether knee
and hip OA, which affect over a quarter of people aged 55 and over
in Western nations, will have a similar impact on the health of
Chinese elders. To address these issues, we undertook a com-
parative prevalence and risk factor study of OA in Chinese and US
Whites.
Methods: We surveyed a random sample of 2,517 (82%
response) men and women (60%) in Beijing using questionnaires,
x-ray methods and reading protocols from prior studies of OA in US
Whites, which provided comparison samples: Framingham (knee,
hand), SOF (hip) and NHANES I (hip). Standard definitions of x-ray
OA used in all samples were K & L grade >=2 for OA of the knee
and hand (any DIP, PIP, MCP or CMC-1) and for hip OA a minimum
joint space <=1.5mm, osteophytes plus JSN, or 3 or more radio-
graphic features.
Results: In women, x-ray and symptomatic (Sx) knee OA were
43-45% more common in Chinese than in US whites, but among
men prevalence in Chinese and whites was similar. In Chinese, the
lateral and medial compartments were involved with similar fre-
quency, compared to a 5-7 fold ratio of medial to lateral involve-
ment in Whites. Hip OA was rare in Chinese, with prevalences
80-90% less than in whites. X-ray hand OA was one-third, and
Sx hand OA two-thirds, less prevalent in Chinese. Independent
risk factors for knee OA in Chinese men and women include
overweight, knee injury and heavy physical activity at work.
Occupational squatting in men and nonoccupational squatting
in both genders also increased the risk of knee OA in Chinese
and accounted for some of the high prevalence in Chinese
women.
Table. Crude prevalence of OA in Chinese ages >=65 and age-
standardized prevalence ratios compared with same age US
Whites
the burden of this disease in terms of pain and disability is high and
millions of elderly Chinese are affected. The burden is likely to
continue to grow as the population ages and obesity becomes
more common.
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VALIDATION OF THE OARSI RESPONDER CRITERIA:
RESPONDERS HAVE BETTER OVERALL HEALTH STATUS
THAN NONRESPONDERS
MC Hochberg1, B Bausell 1 , K Frick2 , D Steinwachs2 , B Berman1
1UniversityofMarylandSchoolof Medicineand 2The Johns
HopkinsBloombergSchoolofPublicHealth, Baltimore,Maryland,
USA
The OARSI response criteria were developed utilizing data from
clinical trials of patients with osteoarthritis (OA) of the knee and hip
(Osteoarthritis Cart 2000;8:395-403). They have not been tested in
other data sets, nor have they been validated against other
arthritis-specific or generic health status measures. We used data
from an ongoing randomized 3-arm, 6 month trial of acupuncture in
patients with OA of the knee to test the hypothesis that patients
who fulfilled the OARSI responder criteria would have better
overall health status as measured by arthritis-specific and generic
health status measures. As of April 2002, 254 of 496 patients with
symptomatic knee OA enrolled in this trial had finished 6 months of
therapy and provided complete data for analysis. Patients were
randomized to "true" acupuncture, "sham" acupuncture, or an
education control group; data from all 3 arms of the trial were
pooled for this analysis. Data from the WOMAC OA index, Health
Assessment Questionnaire (HAQ), Medical Outcomes Study
Short-form (SF) 36, European Quality of Life (EuroQoL) and
Patient Global Assessment were available from entry and 6
months and were used in the analysis. Subjects were classified as
responders or non-responders using "Proposition A" for knee oral
NSAIDs with data from the WOMAC OA index. A total of 113 (45%)
patients fulfilled the OARSI Responder Criteria. Comparison of the
outcome measures at 6 months showed that there were highly
statistically significant differences in favor of better arthritis-specific
and overall general health status for responders compared with
non-responders (see Table; P < 0.001 for all comparisons). These
results provide strong evidence for the validity for the OARSI
Responder Criteria, and support their use as outcome measures in
OA clinical trials.
Prevalence Age-standardized Prevalence Age-standardized
X-ray OA prevalence ratio Sx OA prevalence ratio
Knee-Women 46.6% 1.45 ~1.31 - 1.60) 15.4% 1.43 (1.16 -1.75)
Knee- Men 27.6% 0.90 0.75 -1.07) 7.1% 1.02 (0.70 - 1.42)
Hip- Women 0.4% 0.07 (0.01. 0.25l 0.1% NA
Hip - Men 0.8% 0.19 (0.05, 0.49 0.0% NA
Hand - Women 47.0% 0.64 (0.59, 0.69) 5.8% 0.27 (0.21. 0.32)
Hand - Men 44.5% 0.67 (0.61,0.73) 3.0% 0.31 (0.19, 0.69)
Conclusion: While hand and hip OA are uncommon in China
compared to Western populations, knee OA is as, or more,
prevalent in urban Chinese and is likely even more common in
rural areas. Understanding the different patterns of OA prevalence
in Chinese and Whites will likely enhance our appreciation of the
causes of OA and may provide opportunities for prevention. Also,
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Outcome measure
WOMAC Total score
HAQ Pain score
HAQ Disability index
SF-36 Physical Function
SF-36 Role physical
SF-36 Bodily pain
SF-36 General health
EuroQoL Utility score
EuroQoL Health status
Patient global (0-5)
Responders
19.1 (11.0)
0.77 (0.57)
0.38 (0.34)
61.8 (23.0)
71.1 (36.8)
66.7 (17.8)
75.9 (17.8)
0.77 (0.15)
82.1 (13.8)
3.73 (0.80)
Non-responders
1.5 (15.8)
1.41 (0.73)
0.59 (0.45)
38.1 (21.4)
6.9 (40.8)
66.7 (17.8)
64.2 (18.3)
0.57 (0.25)
71.3 (17.1)
2.78 (0.85)
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CYCLOOXYGENASE INHIBITION: WHERE DO WE NEED TO
GO?
Steven B Abramson MD
New York University School of Medicine, Hospital for Joint
Diseases, New York, NY 10003, USA
Soon after the discovery of the inducible isoform of cyclooxygen-
ase (COX-2), the expectation emerged that the development of
new agents that selectively inhibit COX-2 would optimize the
analgesic and anti-inflammatory properties of the NSAIDs, while
minimizing the potential for GI adverse events (mediated by
inhibition of COX-1). The accumulation of clinical data from phase
II and phase III trials, as well as in several recent large post-
marketing outcome trials. support the concept that selective
COX-2 inhibitors are associated with less GI toxicity than nonse-
lective NSAIDs. However, it is now apparent that COX-2 is also
expressed in a variety of noninflammatory tissues, including kid-
ney, brain, neoplasms, bone, and cartilage, particularly under
"physiologic stress" conditions. Therefore, it is not surprising that
clinical studies indicate that selective COX-2 agents, like conven-
tional NSAIDs, cause comparable rates of edema and hyperten-
sion, and may impair compensated renal function in the setting of
congestive heart failure or volume depletion. Moreover, controver-
sies have emerged, resulting from unanticipated outcomes of
scientific investigations that have raised questions about the
superior risk-to-benefit ratio of the coxibs compared to conven-
tional NSAIDs. These include: 1) Do highly selective COX-2
inhibitors predispose to thrombotic events? 2) Does cardioprotec-
tive use of low dose aspirin abrogate the superior GI safety profile
of the COX-2 selective inhibitors? 3) Are there differences among
the coxibs with respect to effects on blood pressure and renal
function? If so, are such effects reflective of the degree of COX-2
selectivity? It is likely that, through the variety of clinical and
experimental studies in progress, we will have substantially greater
insight into these question in the near future. As the issues are
resolved, we will need to better understand the physico-chemical
properties of coxibs and NSAIDs. It is probable that the overall
safety profile of these agents can improve with drugs whose
PKlPD profile favors shorter plasma half-life combined with accu-
mulation at inflammatory sites. Whether the future of anti-
inflammatory treatments will favor COX-2 selective coxibs, or
whether combination therapies (Le., with aspirin, a gastroprotec-
tive agent or an attached nitric oxide releasing moiety) will emerge
as preferred agents will be determined by future studies.
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INTERLEUKIN·17 REGULATES THE LEVEL AND STABILITY
OF CYCLOOXYGENASE-2 (COX-2) mRNA THROUGH
SPECIFIC ACTIVATION OF THE p38 MITOGEN-ACTIVATED
PROTEIN KINASE CASCADE IN TARGET CELLS: Role of
AU-rich sequences in the 3' untranslated region (UTR) of
COX-2 mRNA
W Faour, QW He, JA Di Battista
Divisionof Rheumatologyand ClinicalImmunology,Royal
VictoriaHospital, McGillUniversityHealth Center, Montreal(OC),
Canada
Interleukin-17 (IL-17) is acknowledged as a prototypic 1-cell-
derived pro-inflammatory cytokine capable of activating inflamma-
tory cells and found in abnormally high levels in the synovial fluid
and joint tissues of arthritic patients. Our objective was to isolate
the signaling pathways associated with IL-17-target gene expres-
sion in human chondrocytes (HC), synovial fibroblasts (HSF), and
macrophages (HM). In preliminary work, we observed a rapid (5
mm), substantial (>15-fold), and sustained (>48h) increase in
COX-2 mRNA, protein and PGE2 release following a rh1L-17
signal that was inhibited by SB202190, a selective, cell-permeable
p38 MAP kinase inhibitor and a dominant negative construct of
MEK-3. Western analysis using specific anti-phospho antibodies
revealed that rh1L-17 increased specific phospho-rylation of
kinase intermediates in the p38 MAP kinase pathway only, as well
as the transcription factors CREB-1 and ATF-2. Co-transfection
studies using chimeric CMV-driven constructs of Gal 4 DNA
binding domains fused to the transactivation domain of ATF-2 or
CREB-1 resulted in a 5.1 and a 2.7 fold increase in 5xGal-4 binding
element- luciferase reporter activity following rh1L-17 incubations,
respectively.
Transfection experiments with human COX-2 promoter constructs
revealed a minor element of p38 MAP kinase-dependent transcrip-
tional control after rh1L-17 stimulation. However, when HSF were
activated with rh1L-17 for 6h (steady-state) followed by wash-out,
the elevated levels of COX-2 mRNA declined rapidly «2 h) to
control levels. When rh1L-17 was added to fresh medium, COX-2
mRNA levels remained elevated for up to an additional 4-6 h;
SB202190 compromised the stabilization of COX-2 mRNA by
rhIL-17. Deletion analysis using transfected chimeric luciferase-
COX-2 mkNA 3 '-UTR reporter constructs revealed that rh1L-17
increased reporter gene mRNA stability and translation via
AU-containing distal regions of the UTA. This response was
mediated entirely by a p38 MAP kinase/HSP27-dependent pro-
cess. As such, IL-17 cell signaling is restricted to the p38 MAP
kinase cascade involving transcriptional/posttranscriptionall
translational control of target genes in the cell phenotypes tested.
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AZD3582: ANALGESIC EFFICACY AND GASTROINTESTINAL
SAFETY IN RATS
G Ojteg1, S. Lohmander2, O-G Berge1, A Hallgren1,
J. Hoogstraate i
1AstraZenecaR&D Sodertalje,Sodertalje,Sweden,
2LundUniversityHospital, Lund, Sweden
Aim of the study: To assess the analgesic, anti-inflammatory and
gastrointestinal (GI)-sparing effects of AZD3582 , a COX-inhibiting
nitric oxide donator (CINOD) being developed for the treatment of
acute and chronic pain, after oral administration to rats.
Methods: AZD3582 and naproxen (0.30-100 IJmol/kg) were
administered to male Wistar or Sprague-Dawley rats and com-
pared with vehicle. Effects on pain and inflammation were
assessed in the carrageenan-induced monoarthritis and paw
oedema rat models. GI-sparing effects were assessed after single
and repeated b.Ld. dosing up to 18 days. Segments of the GI tract
were examined macroscopically and haemorrhagic erosions were
scored. Plasma samples were taken and analyzed to determine
systemic exposure.
Results: AZD3582 and naproxen both caused dose-dependent
reductions in carrageenan-induced paw oedema and pain behav-
iour. The anti-inflammatory effects were significant for both drugs
at ~1 0 IJmol/kg, while the analgesic effects were significant for
AZD3582 3IJmol/kg at 3 and 5 h, and for naproxen 3 IJmollkg and
10 IJmol/kg at 3 hand 5 h, respectively. Monitoring of plasma
concentrations showed that the relative bioavailability of AZD3582
versus naproxen was 50-70% in the rat. Oral administration of
AZD3582 markedly reduced acute and chronic gastric and intesti-
nal damage compared to naproxen. Macroscopic examination of
the GI tract revealed erosion and perforation of the small intestine
in rats treated with naproxen at doses ~60 IJmollkg. AZD3582 and
vehicle did not cause any visible intestinal damage, except at the
highest dose of AZD3582 (120 IJmol/kg).
Conclusions: AZD3582 provides anti-inflammatory and analgesic
efficacy in established rat models, which corresponds with pre-
vious results in a mouse model of analgesia, the acid-induced
writhing model. AZD3582 has a low ulcerogenic potential and a
favourable GI safety profile in rats compared with naproxen. The
novel multi-pathway action of AZD3582, of balanced COX inhibi-
tion and nitric oxide donation, may provide a new strategy towards
efficacious and GI-safe drugs.
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EFFECTS OF SC-560, SC-58125 & DICLOFENAC ON
EXPRESSION & AND SYNTHESIZING ACTIVITY OF COX·1
AND COX-2 IN SYNOVITIS TISSUE IN OSTEOARTHRITIS
H Knorth, RE Willburger, RH Wittenberg, K Schmidt, F Schmitz
UniversityClinicSt Josef-Hospital,Bochum,Germany
Aim of the study: To investigate the relative contribution of the
two COX isoenzymes COX-1 & COX-2 to prostaglandin release
from human inflamed synovium in osteoarthritis (OA) in vitro and to
furthermore determine and quantify the effects of COX-inhibitors
on synovial gene expression of COX-1 and COX-2.
Methods: The effects of diclofenac, a COX-unspecific NSAID and
of SC-560 and SC-58125, a selective COX-1 and COX-2 inhibitor,
respectively, on the release of PGE2 & 6-keto-PGF1 a from
inflamed synovial tissue in vitro were compared. Tissue was
obtained from OA patients during total joint replacement (n = 7).
Tissue was incubated for 3 & 6 hours (3rC) at the presence of
0.1-10 ~M diclofenac, SC-560 & SC-58125. Levels of PG were
measured in the incubation media using ELISA. Expression of
synovial COX-1/ COX-2 was determined by means of real time
RT-PCR using the Light Cycler System.
Results: After 3 hours of incubation, untreated synovial tissue
released 329 ± 106 ng PGE2/ g tissue wet weight (ww). 0.1/ 1/ 10
~M diclofenac caused the following inhibition (% inhibition vs.
control, standard deviation not indicated) of PGE2 release: 49.6/
59.9(*)/ 86.3(*) %. 44.4/ 78.8/ 85.3(*) % inhibition was seen for
equimolar SC-560. Inhibitory potency of SC-58125 was 8.1/ 22.1/
52.6(*) % (* P< 0.05 vs. control). After 6 hours of incubation,
untreated synovial tissue released 1024 ± 314 ng PGE2/ g w.w.
0.1/ 1/ 10 ~M diclofenac caused the following inhibition of PGE2
release: 74.5(*)/ 83(*)/ 97.4(*) %. 16.4/ 30.6/ 86.6(*) % inhibition
was seen for SC-560. Inhibitory potency for SC-58125 was 15.4/
62.8(*)/ 96.6(*) %. Comparable data were obtained for release of
6-keto-PGF1a. RT-PCR revealed a stable expression of COX-1
and COX-2 in the incubated synovial tissue compared to synovial
expression of PBGD housekeeping gene.
Conclusion: Though loosing their specific COX-1/-2 selectivity at
1O~M, SC-560/ SC-58125 show time-dependent increase of inhibi-
tory potency during long-term incubation. The 1~M results most
likely reflect COX selectivity, since 30.6 & 62.8 % inhibition for
SC-560 & SC-58125, respectively, roughly add up to a total of 83
% inhibition seen for COX-unspecific diclofenac. At any concen-
tration studied, this NSAID showed the strongest inhibitory
potency. The significant participation of COX-1 in OA synovitis
should be considered, weighing the potency of classical NSAID
against the gastrointestinal safety of selective COX-2 inhibitors.
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A SUBGROUP ANALYSIS BY JOINT OF THE EFFICACY OF
ROFECOXIB VERSUS NAPROXEN IN OSTEOARTHRITIS:
FROM THE "ADVANTAGE" TRIAL
GP Geba1, JR Lisse2 , M Perlman3 , AB Polis1, M Schulz1,
RA Petruschke1 , CS Skalky1 .
1Merck and Co., Inc., West Point, PA USA, 2Universityof Texas
MedicalBranch, Galveston, TX USA, 3Scripps Clinic, La Jolla,
CA, USA
We evaluated comparative osteoarthritis (OA) efficacy in the
ADVANTAGE trial, a study examining the gastrointestinal (GI)
tolerability of rofecoxib and naproxen in the treatment of
patients with various primary sites of OA during a 12-week
period. Patients meeting entry criteria (non-flare design) were
randomized to receive rofecoxib 25 mg qd (n=2785) or
naproxen 500 mg bid (n=2772). The primary endpoint was GI
tolerability as defined by the incidence of discontinuations due
to GI adverse experiences (AEs). OA efficacy was assessed in
all patients by Patient Global Assessment of Disease Status
(PGADS; a 0-100 mm visual analog scale), discontinuations
due to lack of efficacy (LOE), and, in hand OA patients, also by
the AUSCAN OA Hand Index, (three domains: pain, stiffness,
and function scored on a 5-point Likert Scale). Baseline charac-
teristics were similar between treatment groups. The primary
sites of OA were: knee (50%), spine (24%), hand (16%), and
hip (10%). The overall mean change in PGADS from baseline
to Week 6 did not differ significantly between rofecoxib (-11.6
mm) and naproxen (-10.8 mm). Change in PGADS at Week 12
was also not significantly different between rofecoxib (-10.4
mm) and naproxen (-9.6 mm). Change in AUSCAN scores at
Week 12 and discontinuations due to LOE did not differ signifi-
cantly with rofecoxib versus naproxen. Between treatment effi-
cacy similarity was maintained in subgroup analyses performed
by joint based on the PGADS results. Significantly fewer
(p=0.005) discontinuations due to GI AEs were observed with
rofecoxib (5.9%) than naproxen (8.1 %). In patients treated for
three months, rofecoxib 25 mg qd demonstrated superior GI
tolerability compared to naproxen 500 mg bid, while exhibiting
a similar efficacy profile when assessing the entire cohort as
well as across all primary sites of OA.
Moa
INTEGRATIVE MEDICINE-A MATURING SCIENCE
Roland W Moskowitz MD
Case Western Reserve UniversitySchoolof Medicine,
Cleveland, Ohio, USA
Until the last several decades,traditional medicine looked with
disdain on so-called alternative/complementary medicines or non-
medicinal approaches such as acupuncture and manipulation.
Such alternative approaches were generally predicated on the
basis of anecdotal input, with limited scientifically rigorous evalu-
ation. The term "alternative" itself had a pejorative connotation,
separating these therapeutic modalities (and their proponents!)
from accepted allopathic management. Over the past decade, an
increase in open-mindedness, combined with the acceptance that
these alternative approaches required evidence-based support
has led to a significant increase in interest in such approaches.
Clinical studies are, however, impeded by the high cost of well-
designed double-blind studies, and the fact that these therapeutic
agents are generally non-patentable. It is important to separate
out those approaches that are targeted to a specific disease,
and agents intended primarily for "health maintenance"(usually
the target of so-called nutraceuticals).The divisions between
definitions of given agents as a pharmaceutical, nutraceutical or
pharmanutraceutical have become blurred depending on the
study design wherein they are tested. It is reassuring to observe
S4
the high degree of scientific excellence being introduced to
studies of alternative approaches. The present discussion will
review agents which have been the subject of advanced investi-
gation and attempt to develop a perspective of future appli-
cations. Integrative Medicine perhaps is a more fitting term for
alternative,complementary medicine, allowing us to minimize past
prejudices. The large number of Departments of Integrative
Medicine at major schools of medicine attests to the maturing
science in this field of study.
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Discovery and Evaluation of Potential Disease Modifying
Anti-osteoarthritis Drugs Using Surface Plasmon Resonance
Technology
B Shen, S Shimmon, MM Smith, P Ghosh
InstituteofBone and JointResearch, UniversityofSydneyat
Royal North Shore Hospital,Sydney, Australia
Aim of study: Pentosan polysulfates (CaPPS and NaPPS) and
chondroitin sulfates (ChSs) have recently been shown to exhibit
both symptom and disease modifying activities in osteoarthritis, but
their mechanisms of action are still the subject of debate. Protein-
ases including human neutrophil elastase (HNE), which degrade
the collagens and proteoglycans of the cartilage matrix in arthritic
joints, could be targets for these drugs. In this study we compared
the relative inhibitory and binding activity of these drugs to HNE
and other cationic proteins.
Methods: The molecular interactions between NaPPS (of different
origins), CaPPS, ChSs and some other sulfated polysaccharides
with immobilized proteins were studied using a surface plasmon
resonance (SPR) biosensor device (BIAcore2000). HNE or other
cationic proteins (protamine, lysozyme and hyaluronidase) were
covalently immobilized to a biosensor chip using amine coupling
and the binding affinity of drugs was determined using published
methods and a commercial software program.
Results: The binding activity obtained using SPR technology was
compared with the drug inhibitory activity of HNE determined using
a traditional functional assay. The results obtained by the two
independent techniques showed good correlation and indicated
that the degree and position of sulfate ring substitution were major
determinants of HNE inhibition. Both methods afforded the follow-
ing order of potency against HNE: ChSE > Heparin> CaPPS>
NaPPS-B > NaPPS-N >ChSD > ChSA. Significantly, the SPR
biosensor technology also demonstrated enzyme inhibitory differ-
ences between the CaPPS and NaPPS preparations of different
synthetic origins.
Conclusions: The SPR technology offers not only a sensitive and
reproducible means of ranking enzyme inhibitors as potential new
drugs but also provides a bioassay for distinguishing between
sulfated polysaccharides of different synthetic origins.
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MATRIX METALLOPROTEASE 1,3,13, NITRIC OXIDE AND
PROSTAGLANDIN E2 PRODUCTION FROM OA
CHONDROCYTES AND SYNOVIOCYTES STIMULATED BY
INTERLEUKIN-1 B SUPPRESSIVE EFFECTS OF
GLUCOSAMINE-
H Nakamura, M Tanaka, A Shibakawa, T Kato, K Nishioka
InstituteofMedicalScience, St Marianna University,Kawasaki,
Japan
Aim of study: To evaluate the response of chondrocytes and
synoviocytes to IL-1 B in terms of MMP1 ,3,13, NO and PGE2
production, and the effects of glucosamine.
Methods: OA chondrocytes and synoviocytes were collected from
8 patients with knee OA during arthroplasty. Normal chondrocytes
were collected from 7 patients with femoral neck fracture. Cells
were isolated and culture cells were incubated with IL-1 B ?and?
1,10,100 ?g/ml of glucosamine. After 24 hours, supernatant was
collected to measure the levels of MMP1 ,3,13, NO and PGE2. As
a control, dexamethasone and diclofenac were applied.
Results: The levels of all mediators except NO showed no
difference between different cell types at base line. IL-1B stimu-
lated the production of all mediators from chondrocytes and
synoviocytes; however, the response of normal chondrocytes was
low. After the stimulation, largest amount of mediators were
produced in OA chondrocytes. During MMPs, the levels of MMP3
were highest; 100?g/ml of glucosamine suppressed all mediators
from chondrocytes and MMP1 and 3 from synoviocytes.
Conclusion: Whereas all mediators tested are implicated in the
pathogenesis of OA, MMP3 seems to contribute to it most. Glu-
cosamine that has been used for the treatment of OA, may showed
its effects by modulating the production of these mediators.
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TOPICAL GLUCOSAMINE AND CHONDROITIN SULFATE
FOR OSTEOARTHRITIS OF THE KNEE: A RANDOMIZED
CONTROLLED TRIAL
Prof Marc Cohen, Dr Rory Wolfe, Trudy Mai, Dr Daniel Lewis
Mayo Clinic, Jacksonville,FL, USA
Objective: Oral glucosamine has been reported to reduce the pain
from osteoarthritis and may slow radiographic progression of OA of
the knee. While oral glucosamine is readily absorbed, it is subject
to first pass metabolism in the liver and uptake into non-joint
tissues. Chondroitin sulfate is also known to be effective but the
oral route is severely hampered by poor gastrointestinal bioavail-
ability. This trial aims to assess the ability of a topical preparation of
glucosamine sulfate and chondroitin sulfate to reduce pain related
to osteoarthritis of the knee.
Methods: Trialdesign:Single centered, double-blind, randomized,
placebo-controlled trial. Efficacy was assessed using a Visual
Analogue Scale (VAS) for pain as well as the Western Ontario and
McMaster Universities Osteoarthritis Index (WOMAC) and the
SF-36 questionnaire
Intervention:Patients with painful OA of the knee were randomly
assigned to use either a commercially available topical preparation
containing glucosamine and chondroitin sulfate in addition to a
small amount of camphor and peppermint oil or a placebo to be
used "as required" for a period of 8 weeks.
Results: VAS scores indicated a greater mean reduction in pain
for the active preparation group compared to the placebo group at
both 4 weeks (mean change -2.6cm, SO 2.4cm vs -1.4cm, SD
2.4cm) and 8 weeks (mean change -3.4cm, SO 2.6cm vs -1.6cm,
SD 2.7cm). After 4 weeks the difference between active and
placebo groups in their mean reduction from baseline was 1.2
(95% CI: 0.1 to 2.4, p= 0.03) and this difference increased to 1.8
after 8 weeks (95% CI for difference between groups, 0.6cm to
2.9cm; P = 0.002). Based on data from daily diaries the VAS
scores improved at a rate of -0.10cm per week (95% CI: -0.15cm
to -O.05cm) in the placebo group and -0.20cm per week (95% CI:
-0.25cm to -0.15cm) in the active group (p=0.005). The improve-
ment in pain scores for sUbjects in the active group is supported by
a trend towards improvement in the secondary outcome measures.
Adverse events were infrequent, minor and equally distributed
between the two groups.
Conclusions: Topical application of glucosamine and chondroitin
sulfate is effective in relieving the pain from osteoarthritis of the
knee and improvement is evident within 4 weeks.
Acknowledgment: This research was supported by grants from
Nutrasense Australia Pty Ltd and Smart Science Laboratories Inc
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Supplementary Vitamin E does not affect the loss of
cartilage volume in knee Osteoarthritis: a 2 year
double·blind randomized placebo controlled study
AE Wluka1, S Stuckey2, FM Cicuttini1
1DepartmentofEpidemiologyand PreventiveMedicine, Monash
University,and 2MRI Unit, AlfredHospital,Melbourne,Australia
Aim: To investigate the effect of Vitamin E supplementation on
knee cartilage volume in subjects with osteoarthritis (OA) of the
knee in a randomized, double blind, placebo controlled trial.
Methods: 136 subjects with knee OA (ACR clinical and radio-
graphic criteria) were randomised to receive Vitamin E (500IU) or
placebo for 2 years. Tibial cartilage volume was measured, using
MRI, at the beginning and end of the study.
Results: Apart from there being more women in the Vitamin E
group (42 (63%) vs 33(48%), baseline characteristics were similar
in the 2 groups (67 Vitamin E, 69 placebo). One hundred and
seventeen subjects (59 Vitamin E, 58 placebo) completed the
study. Loss of medial and lateral tibial cartilage was similar in
subjects treated with Vitamin E and placebo (Mean difference +
SO. Medial 157 + 209~m3 versus 187 + 220~m3 on placebo, p ::;
0.51. Lateral 186-+ 258~m3 versus 251 +216~m3, p = 0.19). There
were no significant differences betweenthe Vitamin E and placebo
treated groups in improvement of symptoms from baseline. Dietary
levels of anti-oxidants (Vitamin C, beta carotene, retinol equiva-
lents) had no effect on cartilage volume loss.
Conclusions: Vitamin E does not appear to have a beneficial
effect in the management of knee OA: it does not affect cartilage
volume loss or symptoms. Further research is required into the
possible role of supplementation of other dietary anti-oxidants in
the treatment of knee OA.
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POST·GENOMIC ERA OF MEDICINE: FOLLOWING THE
SCENT IN SEARCH OF THE ETIOLOGICAL GENE(S)
Attur MG,1, Dave MN,1 Akamatsu M,2 Tsunoyama K,2 Iwasaki M,2
Nishimura K,2 Kobori M,2 Yokota, H,2 Kanoh H,2 Miki J,2
Steiner G,1 Stuchin S,1 Katoh M,2 Amin AR1
1NYU SchoolofMedicine/Hospitalfor JointDiseases,
DepartmentofPathologyand Medicine, New York, NY, USA; 2
MolecularMedicineLaboratories,YamanouchiPharmaceutical
Co. Ltd., Tsukuba, Ibaraki, Japan
Aim of StUdy: To identify differentially expressed mRNA and
protein in normal and OA-affected cartilage using a "System
Biology Approach to Genomics".
Methods: Various techniques such as Affymetrix Gene Chip
Technology, SAGE, DD-PCR, highthroughput primary and sub-
tracted cDNA library sequencing and proteomics on a bioinformatic
platform have been utilized. More than 30,000 genes have been
screened using these complementary methods. Validation of these
targets was performed by Real Time PCR and proteomics. Six
different buffers were tested for protein extracted from cartilage for
proteomic analysis. One was selected after running a 2-D gel/
LCMS of cartilage extract, chondrocytes ± IL-1 and synovial fluids.
SNP analysis of DNA from normal and OA individuals was per-
formed using a SYQENONE system. Functional and pharmacog-
enomics analysis of novel targets (for pharmacological intervention
and gene therapy) were characterized in detail in human cartilage
explants.
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Results: Gene-mining efforts generated significant amounts of
correlative data with OA. Approximately 1,500 transcripts were
differentially expressed in normal and OA-affected cartilage (n=20-
80). Using all the above technologies, cartilage and (OA)-disease
specific dysfunctional transcripts were identified by microarray
analysis. Among these, 71 were validated by Real Time PCR. 7%
were always dysfunctional in all OA samples and 44% were found
to be expressed in a variable (> 50%) fashion in OA-affected
cartilage. Proteomic analysis of normal and OA-affected cartilage
proteins, chondrocytes and synovial fluids identified known dis-
ease related protein spots and others not reported to be involved in
the pathophysiology of OA. Pharmacogenomic analysis of differ-
entially expressed genes with known "Anti-Rheumatic Drug" in
vitro was used to curate the data. Functional genomic analysis was
performed for some potential targets. These include TNFa conver-
tase, IL-1 family receptors, Osteopontin, a5ii1 and avii3 integrins,
High Mobility Group-1 Protein and Cyclooxygenases.
Conclusion: Gene expression pattern of OA cartilage as com-
pared to normal showed a complex "inflammatory and proliferation
signature" representing various stages of chondrocyte ontology. In
situ hybridization confirmed some of these targets. The post-
genomic era of functional genomics (Functionomics) will need to
narrow the bridge between correlative data and causative data.
This will require a "System Biology Approach" integrating interac-
tomes of interacting and interdependent disciplines forming a
unified whole. Several proteins present in the synovium were
identified in the cartilage (by proteomics) to demonstrate the
influence of joint fluid in the pathophysiology of the disease. In
summary, OA cartilage can be viewed as an inflamed/proliferative
tissue, brimming with phylogistic products that could serve as
targets for future pharmacological intervention. Thus, the dilemma,
which conceptual framework shall we choose, osteoarthritis or
osteoarthrosis? The implications are clear; exciting interventional
'anti-inflammatory' strategies for the former, pharmacological nihil-
ism for the latter.
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ALTERED GENE EXPRESSION IN OSTEOBLAST·L1KE MG·63
CELLS SUBJECTED TO CYCUC HYDROSTATIC PRESSURE
VTasevski, JM Sorbetti, K Paulson, JF Wang, NG Shrive,
DA Hart
McCaig Centre for JointInjuryandArthritisResearch, Facultyof
Medicine, Universityof Calgary, Alberta, Canada
It is well known that bone cells normally function in a biomechani-
cally active environment, and that an altered mechanical environ-
ment, such as in osteoarthritis, can contribute to bone remodelling.
To better understand the relationships between bone cell metab-
olism and mechanical loading, the effect of intermittent cyclic
hydrostatic pressure (HP) on mRNA levels for a subset of genes,
potentially involved in bone remodeling was investigated. The
influence of various loading protocols on the expression of 12
genes inclUding Matrix Metalloproteinase-I and 3 (MMP-I, MMP-3),
Collagen cxl (col I), and Osteocalcin (OC) was measured in the
human osteoblast-like MG-63 cell line.
Methods: Cells were seeded into modified 6-well culture plates at
2 x 100 cells per well, grown for 2 days in DMEM + 10% FCS
media, transferred to serum free medium for 20 hours, then placed
into the apparatus and subjected, at 3JOC, to cyclic HP for one
minute (0-0.8 MPa at 1Hz) then 14 minutes at rest, for 4, 8 and 12
hours. Control cells remained in serum free media, at 37°C, for
corresponding times. RNA was extracted and RT-PCR performed
using validated primer sets for assessing the 12 human mRNA
species. Significance was established using a t-test with unequal
variances. Experiments were performed in triplicate at least twice.
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Results: Cyclic HP significantly increased (p <0.001) mRNA for
both MMP-1 and MMP-3 at all time points. The increase measured
for MMP-1 was maximal after 4-8 hours, whereas MMP-3
increased further up to 12 hours. Levels of mRNA for Col I and OC
were unchanged at 4 and 8 hours, but were significantly lower (p
<0.001) at 12 hours. mRNA levels for GAPDH and the other 7
genes were unchanged. These effects were not restricted to
MG-63 cells, as similar changes in MMPs were detected in primary
connective tissue cells, when subjected to the same conditions.
Conclusion: Cyclic HP significantly altered gene expression for
some, but not all of the genes assessed. Previously, it has been
shown that expression of both MMP-I and -3 is down regulated in
explants of connective tissues under the same conditions. Altered
gene expression in human osteoblast-like clonal cells under cyclic
HP, further support a role for mechanobiology in the regulation of
gene expression in conditions such as osteoarthritis.
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SUPPRESSION OF CHONDROCYTE-CHARACTERISTIC
GENE EXPRESSION BY IL·1 IS MEDIATED THROUGH THE
TRANSCRIPTION FACTOR C/EBP
Ken Okazaki, Linda J Sandell
Departmentof OrthopaedicSurgery, Departmentof Cell Biology
and Physiology,WashingtonUniversitySchoolofMedicine,
Barnes-JewishHospital, St. Louis, MO. 63110, USA
Cartilage-derived retinoic acid-sensitive protein (CD-RAP) and
Type II collagen are secreted proteins expressed primarily by
chondrocytes: the expression of both is repressed by interleukin 1~
(IL-1~).
To investigate the transcriptional mechanism by which CD-RAP
expression is suppressed by IL-1~, deletion constructs of the
CD-RAP promoter were transfected into rat chondrocy1es and
incubated in the absence or presence of IL-1~.
The results revealed an IL-1 ~-responsive element located between
-2138 and -2068 bp. As this element contains CAAT/enhancer-
binding protein (C/EBP) motif, the function of C/EBP~ and C/EBPIi
was examined. IL-1 ~ stimulated the expression of C/EBP~ and Ii
and the direct binding of C/EBP~ to the C/EBP motif was confirmed
by electrophoretic mobility shift assay. Expression of -2251 bp
CD-RAP promoter construct was down-regulated by
co-transfection with C/EBP expression vectors in a dose-
dependent manner. Mutation of the C/EBP motif within -2251 bp
construct abolished the inhibitory response to IL-1~.
These results suggest that C/EBP is a critical factor mediating
IL-1 ~-induced repression of CD-RAP transcription. C/EBP expres-
sion vectors were also found to down-regulate the reporter con-
struct containing the promoter and enhancer of the type II collagen
gene. The IL-1 ~-induced repression of CD-RAP and type II colla-
gen genes via stimulation of C/EBP~ and Ii were confirmed in
chondrocytes from normal human articular cartilage. Lastly, the
enhancer factor, Sox9, known to be down regulated by IL-1, was
shown to bind adjacent to the C/EBP site competing with C/EBP
binding.
Taken together, these results suggest that C/EBP~ and Ii play an
important role in the IL-1 ~-induced repression of cartilage-specific
proteins in joint disease and that expression of matrix proteins will
be influenced by availability of both positive and negative trans-
acting factors.
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DIFFERENTIALLY EXPRESSED GENES IN HUMAN
ARTICULAR CARTILAGE
Marshall KW, Zhang H, Tang H, Pabalan 0, Loukides J,
Pabalan N, Zhang S, Cukerman E, Liew CC.
ChondroGeneInc., Toronto Western Hospital, UniversityHealth
Networkand InstituteofMedicalScience, Universityof Toronto;
Toronto, Canada
Aim of study: The purpose of this study was to identify genes that
are differentially expressed in cartilage during developmental,
normal and osteoarthritic stages.
Methods: Total RNA from human fetal femoral, norma adult, mild
and severe OA cartilage was extracted using TRlzol reagent.
cDNA libraries were constructed into either A. ZAP Express vector
or A. TriplEx2 vector through a PCR-based method. Phage plaques
were randomly picked and positive inserts were identified by PCR.
PCR products were then SUbjected to automated DNA sequencing
and all generated sequences (expressed sequence tags or ESTs)
were BLAST searched against the public databases.
Results: A total of 57,422 ESTs were obtained for gene expression
profiling, including 13,398 ESTs from fetal, 17,151 ESTs from
normal, 12,651 ESTs from mild and 14,222 ESTs from severe OA.
Over 60% of the ESTs matched to known genes, and about 2%
were putatively novel. Among the known gene matches, we
identified 2,579 unique genes in fetal, 2,518 in normal, 1,938 in
mild and 2,256 genes in severe OA cartilage. Relative EST
frequency level was used to identify differentially expressed genes.
In normal cartilage, as expected, collagen type II was the most
abundantly expressed collagen. Decreases in COL2A1, 9A1, 9A3,
11 A1, and 11 A2 were observed in mild and severe OA. An increase
in COL3A1 was noted in mild OA, while a dramatic increase was
found in severe OA cartilage (Fig. 1). Moreover, mild and severe
OA cartilage have higher expression levels of decorin (DCN) and
lumican (LUM) compared to fetal and normal cartilage. Notably,
proteoglycan 4 is elevated in mild OA, but decreased in severe OA
when compared to normal cartilage (Fig. 2). More importantly, we
observed higher expression of asporin in mild and severe OA
compared to normal cartilage. Surprisingly, we found that CTGF
was abundantly expressed in normal cartilage; however, its
expression decreased in mild OA and dramatically decreased in
severe OA (Fig. 3).
Conclusions: The EST-based approach is a powerful tool for
large-scale identification of differentially expressed genes. To our
knowledge, this is the first report where this approach was applied
to four different types of human articular cartilage. Importantly,
some of the identified genes are found to be associated with OA for
the first time and could be of critical relevance to OA pathogenesis
and progression. The knowledge will help guide us to identify
disease pathways and eventually diagnostic biomarkers and/or
therapeutic targets.
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OSTEOARTHRITIS in the biglycan/fibromodulin double
deficient mouse is associated with increased level of
cartilage oligomeric matrix protein and decreased levels of
decorin and type II collagen in THE ARTICULAR CARTILAGE
L Ameye1.2, M Oliveira1, E Offord1 & MF Young2
1Nestle Research Center, Lausanne, Switzerland;2Craniofacial
and SkeletalDiseases Branch, NlDCR, NIH, Bethesda,
Maryland, USA
Aim: Mice deficient in biglycan and fibromodulin, two small
leucine-rich proteoglycans, start to develop knee osteoarthritis
(OA) by 2 months. During the progression of the disease, the
articular cartilage lesions recapitulate the histological features of
human OA. In order to further validate the use of the double
deficient mouse as an animal model of OA, an immunohistochemi-
cal characterization of the cartilage lesions was initiated.
Methods: Immunostaining for cartilage oligomeric matrix protein
(COMP), decorin and type II collagen was performed on wild-type
and double deficient knees. Two and 6 month-old knees, corre-
sponding respectively to an early and an advanced stage of the
disease in the double deficient mice, were analyzed.
Results: In two month-old wild-type knees, the expression of
COMP was low and restricted to the extracellular matrix above the
tidal mark. Comparatively, this area was more strongly stained in
the two month-old double deficient knees. In addition, in the double
deficient knees, the calcified matrix and its chondrocytes were also
stained but at a lower level. At 6 months, the level of expression of
COMP had increased in the wild-type mice but decreased in the
double deficient mice.
Type II collagen stained the whole articular cartilage matrix and the
chondrocytes in wild-type knees. In double deficient knees, type II
collagen was not detected at the articular surface at 2 months, and
by 6 months its absence had spread to the matrix surrounding the
chondrocytes. Similar, but not identical, patterns of expression
were observed for decorin.
Conclusions: The immunohistochemical results reported here are
similar to immunostainings performed on samples from natural OA
and other animal models. The transient increase in COMP level
observed here has also been reported in Del1 mice, a transgenic
model of OA and in natural OA in horses. Superficial loss of decorin
occurs in human OA and the collagen loss pattern reported here
mimics the degradation pattern of type II collagen in human OA.
Taken ·'together, our data support the use of the biglycan/
fibromodulin double deficient mouse as an animal model of OA.
M18
LONG TERM HIGH-DOSE ASCORBIC ACID INTAKE IN THE
HARTLEY GUINEA PIG INCREASES SPONTANEOUS
OSTEOARTHRITIS SEVERITY
VB Kraus1 , AG Clark2 , JL Huebner1, T Stabler1
Departmentsof 1Medicineand 2Pathology,Duke University
Medical Center, Durham, NC USA
Aim: To investigate the effects of 8 months' exposure to low,
medium and high doses of ascorbic acid on the in vivo develop-
ment of histological knee OA.
Methods: The Institutional Animal Care and Use Committee
approved all aspects of this study. Forty-six male Hartley guinea
pigs were fed diets with "Iow" (2.5-3 mg/day, n=13), "medium" (30
mg/day, n=14) and "high" dose (150 mg/day, n=16) from age 4 to
12 months. The low dose represents the minimum amount needed
to prevent scurvy. The medium dose is the amount present in
standard laboratory guinea pig chow. The high dose is the amount
shown in previous studies to slow the progression of surgically
induced OA in the guinea pig. Blood was collected at 4, 7, 10 and
12 months. Synovial fluid samples and knee joints were harvested
at 12 months of age. Cartilage oligomeric matrix protein (COMP)
was quantified in guinea pig synovial fluid by competitive ELISA
assay with monoclonal antibody 12C4, which we found cross-
reacted to guinea pig COMPo Hydroxyproline of cartilage, reflective
of collagen content, was quantified by HPLC.
Results: Plasma analyses indicated successful dietary regulation
of ascorbic acid levels . The mean total histological score was
highest in the high dose group. When the total histology score for
each animal was plotted against the mean plasma ascorbic acid
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level for that animal, there was a significant correlation (R=0.36,
p=0.02). Synovial fluid COMP correlated with the severity of
histologic disease (r=0.34, p=0.02) and increased with ascorbic
acid dose (p<0.001 using test for linear trend). The mean/(SEM)
hydroxyproline content of cartilage (mg/mg dry weight) increased
across the dosage groups . Pairwise comparisons by ANOVA
showed a significant increase in tissue hydroxyproline content in
the high dose relative to the low dose animals (p <0.05).
Conclusions: Ascorbic acid increased cartilage collagen content
in vivo, however, in contrast to surgically induced OA in the guinea
pig, increased dietary intake of ascorbic acid worsened spon-
taneous OA.
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QUANTITATIVE IN VIVO MAGNETIC RESONANCE IMAGING
TO ASSESS DISEASE MODIFICATION IN THE GUINEA PIG
MODEL OF OSTEOARTHRITIS
J Bowyer, N Brownrigg, R Pickford, R Westwood, J Tessier,
J Waterton, RA Maciewicz
Respiratory& InflammationDepartment,Astrazeneca,Alderfey
Park, UK
Aim of the study: To assess longitudinally, the effect of a
metalloproteinase inhibitor (MPi) on joint integrity and cartilage
destruction using in vivo magnetic resonance imaging (MRI).
Methods: Male, adult, Dunkin Hartley guinea pigs (9 months of
age) were dosed for 66 days with vehicle (20% (vlv) DMSO, 60%
(vlv) PEG400, n=16)) or 0.3mg/kg/day of a MPi (n=IO) via an
osmotic mini-pump. Fat-suppressed MR images covering the
entire left knee were acquired under halothane anaesthesia pre-
and post-dosing using a 4.7T Varian 'Inova'. Three blinded seg-
menters used in-house software to determine cartilage volume on
the medial tibial plateau (MTP) of the right knee. Histological
assessment, using H&E stain, was performed on the left knee after
fixation in 10% formalin and paraffin embedding. Indian ink staining
was used to assess gross anatomical changes to the right tibial
plateau.
Results: The animals remained healthy throughout the study.
Similar weight gained ([]5%) was observed in each group. The
vehicle dosed group lost 20.1±3.0% (mean+sem) of its MTP
cartilage. This equates to a loss in cartilage volume of
0.47±0.08mm3 . Over the same period of time the MTP cartilage of
the MPi dosed group increased by 0.28±O.04mm3 or 16.8±3.0%
(P<0.001, two-sided !-test). Visual assessment of the MR images
indicated that the growth plate was closed prior to dosing, and the
MTP size remained unchanged during the study. However, the
cartilage MR signal intensity (water content) appeared brighter
on the MTP in the MPi dosed group. This was not the case for
the lateral tibial plateau where no difference was noted between
the two treatment groups. Macroscopic assessment confirmed the
MRI results: the area of damage on the MTP cartilage lesions in
the vehicle group (23.8±3.8%) was markedly reduced after MPi
administration (15.9±3.4%; P<0.067). Histological assessment
indicated that the MTP cartilage from the MTPi dosed animal
cartilage appeared 'normal'.
Conclusions: 3D MR image acquisition and segmentation
allowed accurate in vivoquantification of MTP cartilage volume in
a guinea pig model of osteoarthritis. Treatment with an MPi
resulted in an unexpected increase in MTP cartilage volume. The
likely explanation is that the MPi inhibited the degradative and
not the reparative process. These data show that the disease
modification effects of an MPi can be assessed using MRI.
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PROSTHESES SURFACE·ACTIVE PHOSPHOLIPID:
DEFICIENCY IN OSTEOARTHRITIC JOINTS, USE TO
REVERSE JOINT DEGENERATION IN HORSES AND ITS
LUBRICATION OF IMPLANTED PROSTHESES
BAHilis
PaediatricRespiratoryResearch Centre, Mater Children's
Hospital, Brisbane,Australia
There is now much evidence to support the concept that the
outermost hydrophobic lining layer of articular cartilage in the joint
is not proteoglycan but an adsorbed oligolamellar layer of surface-
active phospholipid (SAPL) which should now be recognised as
Zone I - see diagram. This is also an excellent boundary lubricant
which can reduce wear and friction under load to levels which are
remarkable by engineering criteria.
We have just completed three studies, the first of which shows how
SAPL is deficient in the cartilage surface of hips (10) and knees (8)
replaced by prostheses at arthroplasty. In the second, in collabor-
ation with orthopaedic surgeons, we have rinsed prosthetic hips
and knees (35) retrieved at revision and have found each one to be
coated with indigenous SAPL but in widely varying amounts.
In the third, in collaboration with veterinarians, we have completed
up to 260 injections of synthetic SAPL into the joints of 160 horses
and, in 80%, have been able to reduce or even reverse joint
degeneration with 100% resolution of effusions.
This has led us to the theory that a deficiency of SAPL is a major
causative factor in OA which can often be reversed by intra-
articular Injections of exogenous SAPL. SAPL also lubricates
prostheses whose failure might also be attributed to SAPL
deficiency; this greatly reduces submicron wear debris in
prosthetic hips.
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MRI AND RADIOLOGICAL FINDINGS
F Cicuttini
AlfredHospital,Melbourne,Australia
Osteoarthritis (OA) is a group of clinically heterogeneous disorders
unified by the pathological features of hyaline cartilage loss and
subchondral bone reaction. Until about age 50, the prevalence of
OA in women and men is similar. After that, OA is more prevalent,
severe and generalised in women. The apparent increase in
women presenting with polyarticular symptoms in middle age
suggests a relationship between the onset of OA and the meno-
pause. The trigger for the appearance of OA in middle-aged
women is unknown but it has been suggested that it may be
related to the hormonal changes occurring at the menopause.
Whether these are active in all cases of OA in women, or are
restricted to the so-called subtypes of OA ("menopausal OA" or
"generalised OA") is unclear.
There has been increasing interest on the effect of oestrogen
replacement therapy (ERT) on the incidence and prevalence of OA
in post-menopausal women. A number of epidemiological studies
examining the effect of ERT on the prevalence of OA have
suggested a protective effect on knee and hip OA, but the results
have not been statistically significant. Recent studies of incident
knee OA have again suggested a risk reduction in women on ERT,
but have failed to demonstrate statistical significance.
Women have less articular knee cartilage than men, matched for
age, BMI and bone size. We have provided additional support for
a potential benefit of ERT on OA. We showed that age-matched
women taking ERT for more than 5 years had more articular tibial
cartilage than women who had never taken ERT, independent of
bone size, years since menopause, age of menopause, body mass
index and physical activity. We speculate that maintenance of knee
articular cartilage might be one mechanism by which ERT protects
against knee OA.
M22
ESTROGEN REPLACEMENT THERAPY AND
OSTEOARTHRITIS IN NON-HUMAN PRIMATES
CS Carlson, KD Ham, *RF Loeser
College of VeterinaryMedicine, UniversityofMinnesota, St Paul,
Minnesota,and *Rush-Presbyterian-StLuke'sMedicalCenter,
Chicago, Illinois,USA
The reported effects of estrogen administration on severity of
osteoarthritis (OA) in animal models are contradictory. Our group
has focused on OA in cynomolgus macaques (Macaca fascicula-
ris) as an animal model for the human disease, and we are
particularly interested in determining the effects of estrogen
replacement therapy (ERT) on this disease. Adult cynomolgus
macaques develop OA naturally, the severity of which increases
with age. Both the natural progression of the disease and the
morphological appearance of the lesions are similar to OA in
human beings. Thus, these animals provide a unique model for the
study of naturally occurring OA. Cynomolgus macaques have a
28-day menstrual cycle, and intact animals have identical hormo-
nal variations to women. Natural menopause occurs at an age that
is close to the life expectancy of these animals; therefore, bilateral
ovariectomy (surgical menopause) is used to model natural meno-
pause. To examine the potential for a role of estrogen in this model,
we examined adult monkey articular cartilage for the presence of
estrogen receptors. Estrogen receptors were demonstrated using
three different techniques (RT-PCR, immunoblotting, and immuno-
histochemistry) and also were shown in cultured chondrocytes to
be functionally active.
We also have demonstrated that ERT in ovariectomized female
monkeys results in significantly higher synovial fluid levels of
IGF-1, IGF-2, and IGF binding proteins 1 and 3 compared with
untreated ovariectomized monkeys, suggesting a potential stimu-
latory effect of estrogen on the IGF system in joint tissues in vivo.
Furthermore, compared with untreated controls, IGFBP-2 produc-
tion was significantly increased in conditioned media of chondro-
cytes cultured from monkeys that had received ERT in vivo, and
this was associated with significantly greater sulfate incorporation.
Most recently, we have examined the effects of long-term ERT on
the severity of OA of the knee joint in surgically postmenopausal
female monkeys. This study included 166 adult female cynomol-
gus macaques that were bilaterally ovariectomized and randomly
divided into three age- and weight-matched treatment groups for a
three year period: 1) PremarinTM-treated group, n=54; 2) soy
phytoestrogen-treated group (n=60); and 3) control group (n=52).
At necropsy, histological lesions of OA in the medial tibial plateau
were graded, and cartilage and subchondral bone thicknesses and
areas were measured. The data were summarized by principal
components analysis and the resulting factors and individual
variables were compared using ANOVA and ANCOVA (age and
weight as covariates). Cartilage lesions of OA were significantly
less severe in the animals given ERT compared with those in the
control group, and this treatment effect remained significant when
adjusted for age and weight. The factor representing subchondral
bone thickness/area was significantly higher, but the number of
osteophytes was lower, in the ERT group compared with the
control group. Soy phytoestrogen treatment had no significant
effect on cartilage or bone lesions of OA.
These results demonstrate that estrogen has a role in OA and that
ERT significantly reduces the severity of lesions of OA in this
animal model of the disease, possibly through a stimulatory effect
on the IGF system.
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HORMONAL MODULATION OF OSTEOCLAST ACTIVITY IN
OA
Steven R Goldring, MD
Beth Israel DeaconessMedicalCenter, Divisionof
Rheumatologyand New EnglandBaptistBone & JointInstitute,
Boston, MA, USA
Osteoarthritis (OA) is accompanied by marked alterations in
remodeling of the juxta-articular bone. These anatomic changes
reflect local abnormalities in bone remodeling that lead to either
increased (osteophytes, subchondral sclerosis) or decreased bone
tissue (bone cysts). There is also evidence, at least during the
early phases of OA, that there may be a decrease in juxta-articular
bone mass. There remains considerable controversy regarding the
mechanisms involved in the pathogenesis of these local distur-
bances in bone remodeling and their role in the progression of OA.
The osteoclast is the principal cell type responsible for bone
resorption under physiologic conditions.
Studies from our laboratory (as well as other groups) have pro-
vided considerable evidence implicating osteoclasts in the patho-
genesis of focal juxta-articular bone erosions in rheumatoid
arthritis (RA) and in animal models of inflammatory arthritis.
However, there is little direct evidence that defines the role of the
osteoclast in the remodeling changes associated with OA.
Recent studies have provided considerable insights into the role
and mechanism of action of sex steroid hormones (including
estrogens), as well as a variety of cytokines and growth factors, in
regulating bone remodeling in both physiologic and pathologic
conditions. Of interest, many of these same molecules also are
involved in modulating chondrocyte function and remodeling of the
cartilage matrix. Of particular interest is the recently described
potent osteoclast-inducing factor, receptor activator of NF-?? lig-
and (RANKL). This ligand is a member of the tumor necrosis factor
(TNF) family of cytokines and its activity is opposed by the
naturally occurring inhibitor osteoprotegerin (OPG) which is a
soluble receptor belonging to the TNF receptor family. Deletion of
the RANKL gene in knock-out mice or blockade of RANKL with
OPG in animal models of RA markedly reduces both focal and
systemic bone loss. Of interest, there is also a marked attenuation
of cartilage destruction, although studies thus far have not shown
a direct effect of RANKL on chondrocyte function.
These results indicate that there is an important relationship
between osteoclastic-mediated bone resorption and articular
cartilage loss in inflammatory arthritis. Similar relationships
likely apply to the progression of OA and insights into the under-
lying relationships between juxta-articular bone and cartilage
remodeling could lead to new and innovative approaches in the
treatment of OA.
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OVARIECTOMY INCREASES NITRIC OXIDE PRODUCTION IN
OVINE PATELLAR CARTILAGE
MA Cake, RA Read, SM Smith*, P Ghosh"
Divisionof Veterinaryand BiomedicalSciences, Murdoch
University,Perth, Australia;*InstituteofBone & JointResearch,
Royal North Shore Hospital, Sydney, Australia
Aim: To determine the effect of oestrogen withdrawal by ovariec-
tomy on cartilage nitric oxide (NO) production.
Methods: 12 adult sheep were used for this study, six of which
were surgically ovariectomised (OVX). After euthanasia six months
post-op, four 3mm discs of full-thickness cartilage were removed
from the patella and cultured in Hams F12/10% FCS for 24 hours.
Media was then replaced (+100pg/ml ovine recombinant IL-IB in
two of the wells) before incubation for a further 48 hours. NO
release was assayed as conditioned-medium nitrite content (Gre-
iss reaction) and corrected for explant DNA content. Similar
cartilage discs were removed from the contralateral patella and
immediately fixed in 10% neutral-buffered formalin. Immunostain-
ing for iNOS (Cayman Chemicals) and nitrotyrosine (Upstate
Biotechnology) was performed on 41-'m sections following proteo-
lytic epitope retrieval. Staining was quantified as the percentage of
positively-stained cells, in the superficial and intermediate/deep
zones.
Results: Ovariectomy significantly increased NO release by both
resting (3.70±2.06 vs 1.26±0.35 nm01/l-'g DNA; p=0.005) and
IL-IB-stimulated (5.65±2.12 vs 3.17±0.47 nm01/l-'g DNA;
p<0.0001) cartilage explants. OVX sheep also showed an increase
in the percentage of cells staining positively for iNOS and nitro-
tyrosine, which was significant in the intermediate/deep zone
(Table 1).
Table 1: % of chondrocytes positively staining for iNOS and
nitrotyrosine in the superficial (S) and intermediate/deep (I/O)
zones
Stain: INOS Nitrotyrosine
Zone: S I/O S I/O
Control 46.7+22.3 11.2+19.7 54.9+16.2 29.9+15.6
OVX 69.3+17.9 45.7+20.3** 70.1+14.3 63.6+21.5*
*p=0.03;** p=0.008
Conclusion: In this study, OVX was found to significantly increase
patella cartilage INOS expression and ex vivo NO release. While
oestrogen is generally thought to be supportive of constitutive NO
release, this and other studies suggest that oestrogen normally
functions to suppress iNOS expression. Given the known deleteri-
ous effects of NO on chondrocytes, these data provide a possible
mechanism for the enhanced progression of OA in post-
menopausal women.
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REPRODUCIBILITY OF FIXED-FLEXION KNEE
RADIOGRAPHY IN OSTEOARTHRITIC PATIENTS
Yves Miaux, Gabriele von Ingersleben, Manish Kothari,
Martine Sieffert, David White, Charles Peterfy
Synarc Inc., San FranciscoUSA
Aim of study: Radiographic joint space narrowing (JSN) is the
primary structural endpoint for disease progression in OA clinical
trials. Different knee positioning protocols have been proposed for
this, including extended anteroposterior (AP), fluoroscopic semi-
flexed AP, semiflexed MTP PA, and fixed-flexion PA. Since the
intra-articular distribution of cartilage loss in OA is heterogeneous,
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Table 1 Knee extensor and knee flexor isometric force Newtons
(%body weight)
ible in all the scanned stifles. Using spin echo sequence, the
SNR as well as delineation of the various joint tissue margins
were better for 8T MR images compared to the conventional
1.51.
Males
60-69 195.6 (21%) 370.5 (48%) 106.6 (13%) 228.9 (30%)
70-79 173.1 (23%) 360.7 (48%) 97.4 (13%) 211.4 (28%)
Females
60-69 147.7 (20%) 252.6 (39%) 79.6 (11%) 155.4 (24%)
70-79 106.8 (15%) 225.3 (38%) 58.5 (8%) 139.2 (23%)
Conclusions: The 8T MR images showed microscopic resolution
of the fine details of the knee joint tissue microstructure such as
intra-cartilage structure, edges of the meniscus, internal structure
of ligament/tendon, and trabecular bone, compared to the images
acquired using conventional technique at 1.5T. The 8T MRI has
the potential to non-invasively visualize early changes and extent
of lesion(s) in joint tissue structure, particularly cartilage, subchon-
dral bone and bone marrow, in disorders such as osteoarthritis and
rheumatoid arthritis.
Knee Flexors
OA Reference
Knee Extensors
OA Reference
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MUSCLE FORCE IN OSTEOARTHRITIS OF THE KNEE
M Fransen, J Crosbie, J Edmonds
St George Hospital,NSW, Australia
Aim: To quantify the difference in lower limb isometric force
between patients with OA knee and their asymptomatic peers.
Methods: Mean isometric muscle force data collected on the most
painful limb of 89 community dwelling older people aged 60-79
years with symptomatic OA knee referred for physiotherapy were
compared with published reference data' on 106 asymptomatic
gender-matched peers. For both the patient and the reference
group, mean peak isometric force of 2 trials of a 5 second 'make'
test was carried out with the participant seated, the foot free and
the knee drawn by gravity into 90° flexion.
ReSUlts: The majority of referred patients with OA knee had a
lengthy symptomatic disease duration (60% > 5 years) and
severe radiographic disease (55% < 2mm medial joint space
width). Males with OA knee reported mean WOMAC pain and
function scores# of 32 whilst females with OA knee reported a
mean WOMAC pain and function scores of 40-42. These patients
with OA knee could attain only a significantly lower 47-58% of
knee extensor and 42-52% of knee flexor force generated by
their age and sex matched peers (all p<0.01) (Table 1). The
difference is even more marked when muscle force is expressed
as a percentage of body weight and changes in pain and
function with advancing age were more closely associated with
this relative force measure compared with changes in absolute
muscle force.
Conclusions: The similar considerable decrease in knee extensor
and knee flexor force demonstrated by people with established
symptomatic OA knee suggests that preventative measures and
rehabilitation should be directed at both muscle groups to optimally
limit damaging impulsive loading and adduction moments on the
knee joint during weight-bearing.
'Andrews RW et al.Phys Ther 1996;76:248-59.
# WOMAC score range: 0 (no pain/difficulty)-100 (severe pain/
diffiCUlty)
the validity of JSN measurement with any of these depends on
there being no change in the position of the femur relative to the
tibia on serial examinations. Fluoroscopic semiflexed AP, semi-
flexed MTP PA and fixed-flexion PA fix the rotation and angulation
of the tibia, but only fixed-flexion PA also fixes angulation of the
femur. Most reports have focused on the alignment of the rims of
the medial tibial plateau for reproducibility of radioanatomical
positioning. In this study we examined the reproducibility of fixed-
flexion radiographs acquired 1 year apart in terms of femoral
angulation and knee rotation as well as tibial rim alignment.
Methods: Knee radiographs of 42 OA patients were acquired one
year apart at a single center using the fixed-flexion technique and
a Plexiglass positioning frame. Minimum JSW, tibial inter-rim
distance, fibulo-tibial rotation, femoro-patellar rotation, femoro-
patellar angulation and femoral intercondylar angulation were
measured manually and independently by two specialized clinical-
trials radiologists.
Results: The mean annual rate of JSN was 0.39 mm (SO = 0.75
mm) / 0.40 mm (0.84 mm), respectively for the two readers. Mean
absolute change in tibial inter-rim distance between baseline and 1
year was 0.47 mm (0.53 mm) /0.59 mm (0.66 mm). Mean absolute
change was 1.22 mm (1.08 mm) / 1.18 mm (0.96 mm) for
fibulo-tibial rotation, 1.95 mm (1.54 mm) /1.97 mm (1.54 mm) for
femoro-patellar rotation, 3.35 mm (2.74 mm) /3.18 mm (2.88 mm)
for femoro-patellar angulation, and 0.99 mm (1.02 mm) /0.91 mm
(0.85 mm) for femoral intercondylar angulation.
Conclusions: Fixed-flexion radiography shows reproducible posi-
tioning in terms not only of tibial angulation but also of rotation and
femoral a~gulation.
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MAGNETIC RESONANCE IMAGING OF KNEE JOINT USING
HIGH FIELD 8 TESLA SYSTEM
A Kangarlu1 11K Gahunia2 P Schmalbrock1 ; R Gilbert1 ;
o Chakeres1
Departmentof Radiology,Ohio State University,Columbus,Ohio,
USA 1 and Departmentof Orthobiologics,DePuy Orthopaedics,
Warsaw, Indiana USA2
Aim: The aims of this study were to 1) develop methods for the MR
visualization of knee joint tissues using a whole body human 8
Tesla imaging scanner; 2) evaluate the quality and reproducibility
of the high-resolution MR images of ex vivo encapsulated goat
stifles; and 3) compare the high resolution 8 Tesla images with the
conventional 1.5 Tesla images.
Method: Six intact, encapsulated goat stifles (right) were obtained
from an abattoir. The ex vivostifles were MR scanned within 24 hrs
of necropsy. The 8T MR images of the stifles were obtained using
a single strut cavity resonator and 20 spin echo sequence with MR
parameters: FOV=15cm, Matrix=1024x1024, ST=1 mm, TR=1000
msec; TE=20 msec; Scan time=10 mins; BW=IOO KHz. At
1.5T (GE, Signa LX), the MR images were acquired using 20
FSPGR with MR parameters: FOV=IOxIO em, Matrix=512x256,
ST=2 mm, TR=1500 msec; TE=20 msec; Scan time=12.5 mins;
BW=31.25 Hz.
Results: The combination of high signal-to-noise ratio (SNR) and
magnetic susceptibility of the high field MRI scanner provided an
opportunity to visualize joint tissues with an unprecedented reso-
lution. The inherent challenges of high field imaging, however,
required elaborate techniques to produce homogeneous images.
We have carried out imaging in RF coil in the coronal plane. This
plane was in a triangular configuration with respect to the
exciting source. As such, remarkably high quality images both in
terms of resolution and contrast at 8T have been obtained.
These images have enabled visualization of goat stifle anatomy
namely, bone marrow, articular cartilage, anterior and posterior
horn of menisci, femoral condyle, tibial plateau, patella, and
patellar tendon. The 8T spin echo images were highly reproduc-
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COMPARISON OF CARTILAGE MORPHOLOGY IN
PROFESSIONAL WEIGHT-LIFTERS AND SPRINTERS WITH
NORMAL VOLUNTEERS SUGGESTS THAT HUMAN
ARTICULAR CARTILAGE CANNOT ADAPT TO MECHANCAL
STIMULATION
C Gratzke, C Glaser, K-H Engelmeier, M Reiser, R Putz,
F Eckstein
InstitutesofAnatomyand of DiagnosticRadiology,LMU
Milnchen, GSF NationalResearch CenterNeuherberg,
OberschleJBheim,Germany
Aim of study: One of the most intriguing questions in muscu-
loskeletal research is whether tissues are able to adapt post-
natally to mechanical stimulation. Animal studies have produced
inconsistent results regarding the functional adaptation of articu-
lar cartilage, but the development of quantitative MR imaging
now permits to address this question directly in the human
system. We tested the hypothesis that professional athletes with
great muscle strength (weight lifters / sprinters) display higher
cartilage thickness and/ or joint surface areas than normal
volunteers.
Methods: We investigated 7 weight lifters (minimum Bavarian
champion, maximum world champion), 7 bob sleigh co-drivers
(minimum German champion, maximum world champion), and 14
normal volunteers, aged 18 to 35 years. Athletes had been starting
training at ages 7 to 13, whereas volunteers had never performed
training of muscle strength at all. Cartilage volume, thickness, and
surface areas, and muscle cross-sectional areas (MCSAs) were
quantifjed with MR imaging and dedicated software. Muscle
strength was analyzed with a Cybex system.
Results: Weight lifters displayed significantly larger quadriceps
CSAs (+ 30%, P < 0.001) and extending muscle strength (+26%,
p < 0.01) than volunteers, and so did the bob-sleigh sprinters
(+25%, p < 0.001 for CSA and +43%, p < 0.001 for strength). When
averaging cartilage values over the entire knee, athletes displayed
no significant differences in cartilage thickness and surface area.
When analyzing single cartilage plates, there was a significant
increase in thickness of patellar cartilage of the weight lifters
(+ 13%, P < 0.01) and the sprinters (+16%, p < 0.01), but no
significant differences in other parameters and/or other cartilage
plates.
Conclusion: Patellar cartilage appears to be the only plate of the
knee with some capacity for functional adaptation of its thickness.
These data suggest that - opposite to muscle and bone - there is
little (if any) room for postnatal adaptation of articular cartilage to
mechanical loading.
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Modulation of Chondrocyte Phenotype In the Initiation and
Progression of Osteoarthritis
Thomas Aigner
CartilageResearch Group, DepartmentofPathology- University
ofErlangen-NilrnbergFRG
Whatever pleomorphism at first sight the cellular reaction pattern
of chondrocytes during the osteoarthritic disease process display,
they can be basically summarized in three categories. First,
chondrocytes can activate or deactivate their anabolic or catabolic
(matrix-degrading) activity by increasing or decreasing anabolic
and catabolic gene expression. These changes have been in the
focus of research activities for years now (Le. synthesis of aggre-
can and collagen type II as well as expression of e. g. various
metalloproteinases). Secondly, chondrocytes can undergo pheno-
typic modulation implicating an overall severely altered gene
expression profile of the cells in the diseased tissue. Thus, many
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cellular markers of fetal chondrocytes (e..g cartilage collagen
types IIA and X) are "newly" expressed in osteoarthritic tissue.
Finally, the chondrocytes can undergo cell death, whether it
is programmed (apoptosis) or not (necrosis); alternatively, they
can proliferate to compensate for cell loss or to increase their
synthetic activity, as cells do in many other tissues of the body as
a reaction to tissue injury. It is a second issue which extracellular
factors or circumstances initiate and promote these events and
which are the intracellular mediators and genes involved in these
processes.
Recent years have provided insights into all the areas addressed
above, which are relevant to the initiation and progression of the
osteoarthritic degeneration process though the exact sequence of
the events remains unclear. An important step forward in osteoar-
thritis research was the introduction of functional genomic
approaches into the research area. Functional genomics will in the
future even more complement traditional biochemistry and molecu-
lar biology and will allow despite many limitations of this tech-
nology to paint "molecular portraits" of osteoarthritic chondrocytes
vivo and in vitro.
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Proteolysis of type IX collagen and loss of biglycan, decorin
and f1bromodulin In progressive articular cartilage
degradation
C Little, I Otterness, C Hughes, B Caterson
CardiffUniversity,Schoolof Biosciences,Cardiff, UK
Introduction: Type IX collagen and the leucine rich repeat prote-
oglycans (LRR-PGs) decorin, biglycan and fibromodulin are local-
ised on the surface of type II fibrils and may proVide steric
protection. Removal of these surface molecules may be a prereq-
uisite for type II collagenolysis. Using models of progressive
articular cartilage degradation we studied the catabolism of aggre-
can, types II and IX collagen, and the three LRR-PGs.
Methods: Articular cartilage from 3-6 month old pigs was cultured
in OMEM ± 10lJg/ml LPS or 1ng/mIIL-1 alpha + 50ng/ml oncostatin
M (IL-1/0SM). The glycosaminoglycan (GAG) and hydroxyproline
(HyPro) content of the medium, extract and cartilage residue were
measured. The proteoglycan and collagen fragments in the
medium and extracts were separated by SDS-PAGE, and immu-
noblotted with specific antibodies.
Results: LPS and IL-1/0SM increased GAG release (p < 0.0001),
with 60-80% of the total GAG released during week 1. There was
no change in HyPro release in control cultures over the 4 weeks.
LPS increased HyPro release during week 4 (p = 0.02), while
IL-1/0SM increased collagen release during weeks 2,3 & 4 (p <
0.05). IL-1/0SM induced a more marked collagenolysis with 60%
of total collagen released after 4 weeks compared with 20% in LPS
cultures. Immunoblotting with neoepitope antibodies demonstrated
that the GAG release induced by both LPS and IL-1/0SM was due
to increased aggrecanase and not MMP cleavage of aggrecan.
During weeks 2-4, MMPs secondarily cleaved aggrecanase-
generated G1 metabolites. The HyPro release induced by both
agents resulted from collagenase cleavage of type II collagen.
1I-1/0SM and LPS induced loss of biglycan from the cartilage from
week 1 and 2 onwards, respectively. This biglycan loss preceded
the type II collagenolysis induced by both agents. There was a loss
of decorin, fibromodulin and type IX collagen from the cartilage
induced by both IL-1/0SM and LPS, which occurred concomitant
with type II collagen degradation. There was little evidence of
degradation of the LRR-PG core proteins in association with their
release from the cartilage matrix. In contrast all of the released
type IX collagen showed evidence of proteolysis with loss of the
NC-4 domain.
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Conclusions: Proteolysis of type II collagen fibrils is preceded by
aggrecan and biglycan release form cartilage, while loss of deco-
rin, fibromodulin and type IX collagen occurs coordinate with type
II collagen catabolism. Studies utilizing proteinase inhibitors are
now aimed at identifying the mechanismslproteinaseas respon-
sible for loss of the fibril associated molecules in progressive
cartilage degeneration.
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MULTIPLE INTERACTING IL-1B-INDUCED TRANSCRIPTION
FACTORS CONVERGE TO SUPPRESS CONSTITUTIVE
COL2A 1 PROMOTER ACTIVITY
MB Goldring, L Tan, BK Choy, M Osaki
BI DeaconessMed Ctr, HarvardInstofMed, Boston,MA, USA
Aim: IL-1 b inhibits expression of the type II collagen gene
(COL2A1) in chondrocytes following induction and activation of
multiple transcription factors. Our goal was to determine whether
these factors interact directly or indirectly with the COL2A1
promoter.
Methods: Immortalized human chondrocytes (C-28/12) were tran-
siently transfected with deletion and mutation constructs in the
pGL2 reporter vector containing COL2A1 sequences spanning
-577 to +3426 bp. The binding of nuclear factors in IL-1-treated
cells or recombinant proteins to probes containing COL2A1 ele-
ments or consensus sites was analyzed by EMSA. Cotransfections
with expression vectors encoding wild-type or dominant-negative
mutant proteins provided functional characterization.
Results: Inhibition by IL-1b was retained in the -5771+125 bp
promoter region in the absence or presence of the 309 bp intronic
enhancer and was associated with induction of Egr-1, NF-kB and
ESE-1-binding activities in nuclear extracts. Egr-1 bound to sites
within the -131 bp proximal promoter overlapping with Sp1 sites.
ESE-1 bound to 2 sites within -403/-131 bp. In cotransfections,
IL-1 was required for inhibition of promoter activity by pCMV-Egr1,
whereas pCI-ESE1 by itself mimicked the IL-1 effect. Dominant-
negative Egr-1, ESE-1 and srlkB vectors reversed the inhibition
either completely or partially. However, NF-kB was found to act
indirectly by inducing ESE-1 promoter activity and subsequent
ESE-1 mRNA expression. Furthermore, constitutive Sox9, L-Sox5
and Sox6 mRNA levels were not suppressed by IL-1 in this culture
model.
Conclusions: Our results show that Egr-1 acts by reducing the
strong constitutive activity of the core COL2A1 promoter by com-
peting with Sp1 for binding and thus permits the direct effects of
IL-1-induced transcription factors via sites distal to the proximal
promoter. The rapid response observed is consistent with early
cytokine-activated events that are usually associated with positive
responses but produce a negative response in this promoter
context by preventing interactions with constitutive factors. We
conclude that the novel ETS factor, ESE-1, is the critical IL-1 b-
induced factor that directly suppresses COL2A1 transcription and
that it serves a repressor function via specific protein-DNA and
protein-protein interactions involving both constitutive factors
and other IL-1 b-induced transcription factors.
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FACILITATED GLUCOSE TRANSPORT AND CHONDROCYTE
ACTIVATION
AR Shikhman1.2 , D Brinson1 , M Lotz1
1 Divisionof ArthritisResearch, The Scripps Research Institute,
La Jolla, CA, USA
2 DivisionofRheumatology,ScrippsClinic, La Jolla, CA, USA
Glucose plays a pivotal role in chondrocyte differentiation, survival
and extracellular matrix synthesis. Transmembranous glucose
transport facilitated by glucose transporter proteins or GLUTs
represents the first rate-limiting step in glucose metabolism.
Recently, we demonstrated that four distinct GLUTs are detectable
in human articular chondrocytes. These include cytokine-inducible
GLUT1 and GLUT9, and constitutively expressed GLUT3 and
GLUT8. IL-1 B-accelerates glucose transport in chondrocytes,
increases GLUT1 mRNA and protein expression as well as GLUT1
protein N-glycosylation and plasma membrane incorporation. The
stimulatory effect of IL-1B on glucose transport in chondrocytes is
mediated via cooperative interaction of protein kinase C and p38
MAP kinase pathways, and does not depend on nitric oxide and
eicosanoid production. In contrast to IL-1B, TGFb1 - or IGF-1-
increased glucose transport in chondrocytes is not associated with
the up-regulated GLUT1 expression and is mediated via an Erk
kinase-dependent mechanism. Expression of GLUT1 protein is
markedly increased in human articular cartilage affected by oste-
oarthritis as compared to normal cartilage. Increased expression of
GLUT1 is also detected in the articular cartilage from rabbit knees
affected by experimentally-induced osteoarthritis. Inhibition of glu-
cose transport in human chondrocytes with the glucose analogue
2-deoxyglucose suppresses GLUT1 membrane incorporation and
inhibits chondrocyte activation by IL-1Bas measured by nitric
oxide, IL-6, hexosaminidase and pro-MMP-1 production. Further-
more, pretreatment of bovine cartilage explants with
2-deoxyglucose completely prevents cartilage matrix degradation
induced by IL-1. The anti-inflammatory effects of 2-deoxyglucose
are reversible and do not depend on inhibition of glycolysis.
Inhibition of glucose transport in chondrocytes also suppresses
chondrocyte proliferation and glycosaminoglycan synthesis
induced by TGFB1 and IGF-1. The 2-deoxyglucose effect is
mediated in part via inhibition of Jnk, Erk and p38 MAP kinase
phosphorylation. Results of this study demonstrate that facilitated
glucose transport represents a novel mechanism regulating
chondrocyte activation by cytokines and growth factors.
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BY INTERLEUKIN-1 VIA THE P38 MITOGEN-ACTIVATED
PROTEIN SIGNALING PATHWAY IN AN ISOFORM-SPECIFIC
MANNER MICROSOMAL PROSTAGLANDIN E SYNTHASE IS
EXPRESSED IN HUMAN CHONDROCYTES UNDER
REGULATION KINASE
K Masuko-Hongo, F Berenbaum, L Humbert, C Salvat,
M Goldring', S Thirion
UMR CNRS 7079, UniversitePierre et Marie Curie (Paris VI),
Paris, France; 'Beth Israel DeaconessMed Ctr, Boston, USA
Aim: To investigate the expression and the regulation of the
inducible microsomal prostaglandin E synthase (mPGES) in
human chondrocytes.
Methods: Expressions of mRNA and protein mPGES were ana-
lyzed in cultured immortalized human costal chondrocytes (T/C-
28a2 cell line) using northern blot and immunoblot, respectively. To
investigate the effect of an inflammatory cytokine on these expres-
sions, chondrocytes were stimulated by recombinant human
IL-1beta (IL-1B) with or without pretreatment by various MAPK
inhibitors. Levels of prostaglandin E2 (PGE2) secreted in culture
medium after IL-1B stimulation were measured using EIA assay.
Results: IL-1B was found to upregulate the expression of mPGES
both at mRNA and protein levels in a dose- and time-dependent
manner which was in parallel with an increased secretion of PGE2.
The p38 MAPK inhibitor SB203580 significantly suppressed IL-1 B-
induced PGE2 synthesis and IL-1 B-induced mPGES expression.
However, specific inhibitors for the alpha isoform (SC906 and
SC335A) of p38 MAPK did not exhibit this inhibitory effect on
mPGES expression, suggesting that, in chondrocytes, IL-1B trig-
gers the expression of mPGES via a non-alpha-p38 MAPK path-
way.
Conclusions: In human chondrocytes, IL-1B induces mPGES,
mainly through a p38 MAPK signaling pathway, in an isoform-
specific manner. The mPGES enzyme could be considered as a
novel therapeutic target in order to block the catabolic and inflam-
matory properties of PGE2 in cartilage.
This work has been funded in part by a grant from Pharmacia.
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Articular chondrocyte proliferation and cyclin D expression
MC Stewart
Departmentof Orthopaedics,Case Western Reserve University,
Cleveland, USA.
Aims: Cell proliferation is critical to tissue homeostsis and repair.
Our aims were to identify the critical D type cyclins (CD) that
control articular chondrocyte (AC) proliferation, identify mecha-
nisms that control expression of these cyclins, assess the effects of
of CD1 over expression in ACs.
Methods: 1. D type cyclin expression profiles were determined in
total RNA samples isolated from human AC samples and isolated
chondrocytes obtained from total joint replacement patients, using
semi-quantitative RT-PCR. 2. Changes in expression of the D type
cyclins under differing in vitro conditions (monolayer vs suspen-
sion, +/- FBS) were assessed by Northern and Western blot
analyses. 3. Effect of DNA methylation status on intrinsic cyclin D
expression was assessed by 5-azacytidine (5-AZA) treatment. 4.
Proliferative effects of CD1 over expression was assessed in
bovineACs using a CD1-expressing adenovirus.
Results: 1. Of the three D type cyclins, CD2 was constitutively
expressed in all human cartilage samples, CD1 expression was
variable and was linked to the expression of the proliferative
marker cyclin A and the CDK inhibitor, p21. Further, CD1 expres-
sion was correlated with overt matrix damage. CD3 was not
expressed by ACs. 2. In bovine ACs cultured as serum-free,
non-adherent aggregates, CD1 expression was substantially down
regulated over time, reaching minimally detectable levels by Day
14. CD1 expression was responsive to mitogens (FBS, bFGF), but
the mitogenic response was also lost over time in culture. 3.
Treatment of bovine ACs with 5-AZA for three days resulted in
dose-dependent increases in steady-state expression of both
cyclin D1 and p21. 4. Cyclin D1 over expression did stimulate
some chondrocyte proliferation, however, this response was tran-
sient (1-4 days) and was sUbstantially less than the response of
these cells to bFGF treatment. Significantly, adenoviral CD1
expression was not accompanied by increased p21 expression,
whereas bFGF up regulated expression of both genes.
Conclusions: CD1 is the primary regulated D type cyclin in ACs.
Expression of CD1 is dependent on both substrate provision and
exposure to mitogens. CD1 expression, and AC proliferation, is
minimal in conditions that support the fully differentiated articular
chondrocytic phenotype. Repression of CD1 expression is medi-
ated, at least in part, by DNA methylation status. CD1 expression,
by itself, is insufficient to stimulated chondrocyte proliferation.
Co-expression of the CDK inhibitor/adaptor molecule p21 may also
be necessary for the activation of G1 phase CDKs and consequent
chondrocyte proliferation.
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Suppression of cell death and OA progression by inhibiting
intracellular p38 MAP Kinase in chondrocytes: in vitro and
in vivo evidence
Lei Wei, Xiojuan Sun, Charles, Davis, Qian Chen
Penn State Univ. Coli. Of Medicine
Introduction: Chondrocytes are the only cells in articular cartilage,
and thus responsible for its structural integrity by maintaining its
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extracellular matrix. Osteoarthritis (OA) is characterized by the loss
of chondrocytes and destruction of extracellular matrix in cartilage,
increase of subchondral bone density, and formation of osteo-
phytes. However, the intracellular pathway that leads to cell death
and OA progression is not clear. We test the hypothesis that p38
MAP kinase, a stress kinase activated by pro-inflammatory
cytokines and mechanical stress, plays an important role in regu-
lating chondrocyte death and OA progression.
Material and Methods: For in vitro study, human OA chondrocytes
were isolated from replaced joint cartilage. Anti-Fas mAb was used
to induce cell death, and SB203580 was used to inhibit p38 MAPK
activity. Apoptosis rate was quantified by flow cytometry of
annexin-V positively labeled cells. Activities of p38 MAPK and
ATF-2 were determined by western blot. For in vivo study, three
lines of transgenic mice were generated in which a dominant
negative (DN) p38 MAPK transgene was expressed in cartilage
under collagen II promoter. The joints of transgenic mice were
analyzed by X-ray radiograph periodically during aging.
Results: Treatment of OA chondrocytes in vitro with p38 inhibitor
blocked not only anti-Fas induced apoptosis, but also total cell
death. Concurrently, chondrocyte proliferation was increased.
Activity of p38 kinase was up-regulated by induction of apoptosis
with anti-Fas, and down regulated by inhibition of apoptosis by
SB203580. Induction of chondrocyte apoptosis resulted in the
increase of the activity of caspase-3 and ATF-2, a substrate of p38
MAPK. Suppression of p38 activity completely inhibited the activity
of these factors. In vivo, complete suppression of p38 MAPK
activity in chondrocytes (DNp38 homozygotes) led to the lack of
endochondral bone during development, however, partial suppres-
sion of p38 MAPK in cartilage (DNp38 heterozygotes) inhibited OA
associated symptoms during aging, including the increase of
subchondral bone density and formation of osteophytes.
Discussion: Our study suggests p38 MAPK activity is a key
regulator of cell death and OA progression in cartilage. Repression
of p38 activity inhibits chondrocyte apoptosis by depressing ATF-2
and caspase-3 activity, while elevation of p38 induces apoptosis by
stimulating their activity. Thus, inhibition of p38 MAPK activity
blocks the loss of cells in cartilage by decreasing apoptosis
and enhancing cell proliferation. In vivo data demonstrate
that inhibition of p38 MAPK in chondrocytes leads to suppression
of OA progression. Thus, p38 MAPK pathway is of potential
therapeutic importance as a target for the prevention or treatment
of OA.
M36
ADENOVIRAL OVEREXPRESSION OF TGF·~ AND BMP
INHIBITORS DURING EXPERIMENTAL OSTEOARTHRITIS
A Scharstuhl, E Vitters, P van der Kraan, W van den Berg
RheumatologyResearch Laboratory,UniversityMedicalCenter
Nijmegen, Nijmegen, The Netherlands
The aim of this study was to assess adenoviral overexpression of
TGF-~ and BMP inhibitors on early osteophyte formation, fibrosis
and cartilage proteoglycan (PG) content during experimental
osteoarthritis (OA).
Methods: Adenoviruses expressing the intracellular BMP inhibitor
Smad6 (Ad-Smad6), the intracellular TGF-~ inhibitor Smad7
(Ad-Smad7) or luciferase as a control (Ad-Luc) were used. On day
1, adenoviruses (pfu 1-107 ) were injected in right knee joints of
C57BI/6 mice to transfect the synovial lining. One day later, papain
(1 U) was injected La. to induce experimental OA. After 7 days,
knee joints were isolated and processed for routine histology.
Osteophyte size, fibrosis and cartilage PG content of the lateral
and medial femur/tibia plateau were all measured by a blinded
observer using a computer aided image analysis system.
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Results: Papain injection caused the formation of osteophytes
primarily on two locations; the lateral and medial femur near the
margins of the articular cartilage. Despite a reduction in osteophyte
size in the Ad-Smad6 group compared to Ad-Luc, this did not reach
statistical significance. In contrast, Smad7 overexpression signifi-
cantly decreased osteophyte formation on both locations by -50%
and -60%, respectively, compared to Ad-Luc. Moreover, fibrosis
induced by papain injection was significantly reduced by Smad7,
but not by Smad6 overexpression, compared to Ad-Luc. Strikingly,
although overexpression of Smad6 and -7 was restricted to the
lining, Smad6 increased cartilage PG loss in all articular surfaces
in the order of 30-40%, compared to the Ad-Luc group. Smad7
overexpression also increased PG loss, although the overall effect
was smaller than after Smad6 overexpression.
Conclusions: Since Smad7 and not Smad6 reduced osteophyte
size, the major contributor to early osteophyte formation is most
likely TGF-~. TGF-~ also seems the primary factor responsible for
fibrogenesis during experimental OA. Interestingly, inhibition of the
TGF-~/BMP signaling pathway in the lining affected cartilage PG
content. Most likely, inhibition of TGF-~/BMP signaling leads to
altered growth factor expression in the lining, which results in
enhanced cartilage PG loss.
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Difference In early expression of c-fosgene via Increase of
Intracellular Ca2 + ion reflects repair potentials of superficial
defects on articular cartilage in fetal and adult rats
Nobuyuki Kumahashi 1 , Mitsuo Ochi1 •2 , Hiroko Kataoka1 ,
YUji Uchio', Hiroyuki Kakimaru 1, Koh-ichi Enomot03
1Departmentof Orthopaedicsand 3Departmentof Physiology,
Shimane Medical University, Izumo, Japan; 3Department of
OrthopaedicSurgery, HiroshimaUniversitySchoolof Medicine,
Hiroshima,Japan.
Aim of Study: Superficial defects in adult articular cartilage do not
heal, but similar injuries in the fetal knee heal spontaneously. To
clarify the early process of healing, we investigated the relation-
ships among the repair capacity, early induction of c-tos gene
expression and intracellular Ca2 + ion (i) after the injury in adult and
fetal rat articular cartilage.
Methods: Partial defects of 150 to 200~m-deep were created on
the surfaces of the knees of adults and E19 fetuses. The repair
process from 1 to 48 hours after the operation was histologically
observed, and the expression of c-tosmANA was analyzed using
AT-PCA and in situ hybridization. Chondrocytes were isolated from
5-week-old rat joints and cultured. The c-fos expression after
application of purinergic agonist ATP and Ca2+ ionophore A23187
was measured. The effects of ATP on i was observed using fura-2
fluorescence image.
Results: The defects in the fetuses were almost repaired within 48
hours, but that did not occur in adults. In fetuses, the c-tosgene
expressed in chondrocytes just around the wound. It started 1 hour
after the 'injury and continued for 6 hours. The region expressing
c-fosexpanded on the surface of cartilage. In contrast, no obvious
c-tosexpression was observed in adults, for up to 48 hours. ATP
and A23187 elicited the immediate expression of c-tos in primary
cultured chondrocytes. When ATP was applied to cartilage slices,
fetal chondrocytes showed transient increase of i, whereas adult
cells did not display the response.
Conclusions: The distinct expression patterns of c:tos after
cartilage injury may reflect the repair potentials of fetal and adult
articular cartilage. The ATP responses of cultured chondrocytes
and fetal cartilage suggested a process that the increase of i by the
stimulation of purinergic receptor induced the expression of c-tos.
This process may work only in the repair of injured fetal cartilage.
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PREDICTORS FOR THE INCIDENCE AND PROGRESSION OF
LUMBAR SPINE INTERVERTEBRAL DISC DEGENERATION:
THE CHINGFORD STUDY
G Hassett, DJ Hart, DV Doyle, N Manek and TD Spector
Twin Research& GeneticEpidemiologyUnit, St Thomas'
Hospital, London,UnitedKingdom
Aim: Incidence and progression of the individual radiographic
features of lumbar spine disc degeneration have not previously
been studied. We therefore examined for the rates and predictors
of radiographic incidence and progression of lumbar spine disc
degeneration in a population-based cohort of women.
Methods: 796 paired lateral lumbar spine x-rays taken at entry to
the study and at year 9 were examined. The films were read by one
experienced reader for the individual features of anterior osteo-
phytes (AO) and disc space narrowing (DSN) using the Lane
grading score and an overall Kellgren and Lawrence grade (KL) at
each lumbar disc space L1-5. Prevalent cases were defined as the
presence of KL 2+ or a Lane grade of 1+ or 2+ for either AO or
DSN in at least one of the four disc spaces. Incident cases were
defined as < grade 2+ at year 1 and grade 2+ at year 9.
Progression cases were defined as grade 1+ at year 1 and a
change to a higher grade over the 9 years. Predictors of incidence
and progression including age, body mass index (BMI), smoking,
EAT, physical activity, back pain, presence of OA at the hip, hand
and knee were examined using logistic regression. In the analysis
adjustments were made for age and BM!.
Results: At entry the mean age was 53.8 ± 6 years and BMI 25.4
± 4.0 kg/m2 . There were 19% of new cases defined by AO, and
16% by DSN, giving an average incident rate of 2% per year.
Progression occurred in 25% of cases defined by AO and 34%
defined by DSN. Incident DSN was associated with age, BMI, back
pain (p= 0.02) and baseline A02+. Progression of DSN was
associated with BMI, knee osteoarthritis, baseline A02+ and back
pain (p <0.001). Incident AO was associated with age and BM!.
Progression of AO was associated with age, BMI and baseline
DSN2+.
Conclusions: This is the first population study of the rates and risk
factors for the incidence and progression of the individual features
of AO and DSN of lumbar spine disc degeneration. Aisk factors
include age, BMI, back pain, baseline individual features and
osteoarthritis at other sites. These factors appear to be site and
feature specific.
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CHONDROCYTES OR STEM CELLS?
B Johnstone
Case Western Reserve University,Cleveland, USA
Given the poor reparative abilities of articular cartilage, many
attempts to use cell-based therapies to augment or replace carti-
lage have been made. There is an ongoing scientific debate
regarding the use of stem cell versus chondrocyte-based therapies
for articular cartilage repair/regeneration. It is presently unclear
whether either strategy is useful for the treating cartilage loss due
to either trauma or degeneration.
There are many sources of stem cells and several sources of
chondrocytes that could be used for cartilage repair or regenera-
tion. Many types have been tried, albeit with most strategies
concentrating on isolated chondral or osteochondral defects, in
both the research and clinical settings. Cell-based therapies for
degenerative conditions such as osteoarthritis represent consider-
ably greater challenges, for which little research has been done.
An issue that is often raised concerning mesenchymal stem cells is
the fact that they will differentiate into hypertrophic chondrocytes
and die by apoptosis in both in vitro and in vivo systems that
facilitate chondrogenesis. Thus, it is argued that these cells may
not give rise to articular chondrocytes. However, this may be a
limitation of the systems used, since prevention of the hypertrophy
of these cells can be accomplished in the appropriate conditions.
There are issues related to the commercial possibilities for cell-
based therapies. The time and costs associated with any type of
autograft technique that involves in vitromanipulation outside of
the operating room do not make these techniques commercially
attractive. Our experience with creating tissue-engineered stem
cell cartilage constructs has shown us the difficulties with this
strategy. Although many companies are interested in such tech-
niques, allograft or xenograft cell therapies that might be made into
appropriate "off-the-shelf" products are more desirable. This is true
whether one is considering the use of either stem cells or chondro-
cytes.
Clearly, the stimulation of cells in vivo, or at least within the
operating room setting, is the most desirable therapeutic option.
This could still involve either chondrocytes or mesenchymal stem
cells, since sources of both exist close to or within the joint. For
chondrocytes, the concern is the low cell number available for
stimulation in joints with larger defects or more degenerated
cartilage. For stem cells, the synovium or subchondral bone
marrow are readily accessible sources, as ours and other work
demonstrates. Recent reports of cells with stem cell-like charac-
teristics in the superficial zone of cartilage itself offer another
potenti~1 source of reparative cells. All of these cells may be
amenable to stimulation with appropriate factors that stimulate
chondrogenesis and cartilage extracellular matrix production.
However, such strategies would have to include proliferation at an
early stage, and thus become quite complex to orchestrate.
In summary, the answer to the question posed in the title depends
on the strategy one is pursuing. It is unclear which strategy will
succeed most effectively in cartilage repair and regeneration.
However, it is obvious that more than one strategy will be required
for the many different conditions encountered in joint pathology.
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HOW IMPORTANT IS THE BIOMATERIAL/SCAFFOLD FOR
CARTILAGE REGENERATION?
G Vunjak-Novakovic
MassachusettsInstituteof Technology,CambridgeUSA
Articular cartilage can tolerate a tremendous amount of intense
and repetitive physiological stress, but it also exhibits a striking
inability to heal. Rapid, orderly and mechanically competent resto-
ration of articular cartilage remains a challenge, and it is an open
question whether cartilaginous tissue constructs should be engi-
neered in vitro, or whether cartilage regeneration should be carried
out in vivo. In either case, it is critical that cartilage transplant
contains biosynthetically active cells within a three-dimensional
biomaterial scaffold.
A biomaterial scaffolds for functional tissue engineering is gener-
ally designed to provide a structural template for tissue develop-
ment, to facilitate transport of nutrients, oxygen and regulatory
molecules to and from the cells, and to biodegrade in parallel with
the accumulation of tissue components. Scaffolds investigated to
date vary with respect to material chemistry (e.g., collagen, syn-
thetic polymers), geometry (e.g., gel, fibrous mesh, porous
sponge), structure (e.g., porosity, pore size distribution, orientation
and connectivity of the polymer phase), mechanical properties
(e.g., compressive stiffness, elasticity) and degradation (e.g.,
degradability, degradation rate, degradation products). Scaffold
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chemistry is important because each scaffold is also an informa-
tional template providing specific signals to the cells, by itself as
well as by immobilized growth factors and enzymes. Scaffold
structure is also important as it determines the cell attachment and
function, the transport of chemical species, and in conjunction with
scaffold chemistry the course of scaffold degradation. Scaffolds
should be made of biocompatible, biodegradable materials to
minimize immunogeneicity in vivo. The rate of scaffold degradation
should ideally match the rate of synthesis and functional assembly
of the extracellular matrix, and this rate can depend on scaffold
material and structure, spatial density and metabolic activity of
attached cells. The maintenance of mechanical properties of the
scaffold over the course of tissue regeneration may be critical for
its efficacy, and the scaffold can modulate the stress-strain
environment at the cellular and tissue levels.
This contribution will discuss the general and specific requirements
for biomaterial scaffolds used for functional tissue engineering of
cartilage.
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REPAIR AND REGENERATION OF ARTICULAR CARTILAGE
POTENTIAL APPLICATIONS IN OSTEOARTHRITIS
EVAULATION OF OUTCOMES
Joseph A Buckwalter
Universityof Iowa, Iowa City, Iowa, USA
With the intention of relieVing pain and improving mobility for
people suffering from osteoarthritis, surgeons and scientists have
developed a variety of approaches to restoring cartilaginous articu-
lar surfaces. These approaches fall into two categories: 1) stimu-
lating formation of new cartilaginous tissue, 2) transplanting
chondral and osteochondral allografts or autografts. Recent work
has combined these two approaches to create grafts, pre-formed
in vitro and consisting of matrices containing chondrocytes or stem
cells, that can be implanted in synovial joints. Experimental studies
have shown that multiple variations of these approaches will
restore some form of cartilaginous articular surface in animal
joints, but successful formation or transplantation of cartilaginous
tissues in animals with experimentally created joint surface defects
does not prove that a given method has the potential to relieve joint
symptoms or improve joint function in humans with osteoarthritis.
The information developed form clinical studies thus far is not
sufficient to support the use of any of these approaches in patients
with osteoarthritis. Yet, the effort to restore cartilaginous articular
surfaces has shown enough promise that investigators should now
evaluate the results of methods of restoring cartilaginous articular
surfaces in ways that have the potential to identify the most
promising approaches to the treatment of defined clinical prob-
lems. Important issues concerning experimental models include
the type of articular surface defects studied, the age of the animals
and differences in joints and articular cartilages among species.
Important considerations in assessing the outcome of procedures
designed to restore an articular surface in humans and animals
include the overall function of the individual animal or patient, the
function of the specific joint, the structure of the joint and the
structure, composition and mechanical properties of the new
tissue. This rigorous comprehensive approach to evaluating
methods of restoring cartilaginous articular surfaces is based on
the principle with the goal of any of these methods is sustained
improvement in joint function and decreased joint symptoms in
people with traumatic or degenerative joint damage. It is important
to appreciate that tissues that differ from normal articular cartilage
in structure, biochemical composition and biomechanical proper-
ties may have the potential to function well as an articular surface
despite the fact that they fail to restore a tissue that is identical to
normal articular cartilage.
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Repair of Articular Cartilage Lesions with PolyActive@l 70/30
and PolyActive 55/45 in Rabbits: with and without
Allogeneic Chondrocytes
EJP Jansen 1 , J Hendriks2 , R Haan2 , SK Bulstra1 , J Riesle2 ,
R Kuijer1
1Departmentof Orthopaedicsurgery, UniversityHospital
Maastricht, The Netherlands
21soTis NV, The Netherlands
Introduction: The aim of our study was to assess the performance
of biocompatible and biodegradable PolyActive@lscaffolds (PAl.
polyethylene glycol terephthalate - polybutylene terephthalate
(PEGT-PBT) block copolymers, without or with allogeneic chondro-
cytes in cartilage def6cts in New Zealand White rabbits.
Materials and Methods: PA70/30 and PA55/45 scaffolds were
implanted in 4 mm diameter 'fresh' and 'old' cartilage lesions in 22
female NZW rabbits. The rabbit knees were randomly divided into
a control group, a sham group, a PA70/30 group and a PA55/45
group. An osteochondral defect was drilled in the knees of 6-month
old rabbits and then filled with PolyActive@lor left empty (control).
The follow-up was three months. In the second study the knees of
14 6-month-old rabbits were randomly divided into four groups.
'Fresh' osteochondral defects were left empty (i); treated with an
empty scaffold (PA55/45) (ii); treated with a PA55/45 scaffold
seeded with primary, allogeneic rabbit chondrocytes (iii); or treated
with a scaffold with seeded primary, allogeneic rabbit chondrocytes
which were subsequently cultured (iiii). After sacrifice the femoral
condyles were prepared for histology. Sections were scored using
the histological O'Driscoll score for cartilage repair.
Results: In general the defects were filled with fibro-cartilaginous
tissue on top of incompletely recovered subchondral bone. Inter-
estingly, 88% of the tissues within the PolyActive@l scaffolds, was
bonded to the adjacent cartilage to at least one side of the graft.
From the empty PA55/45 scaffolds in 'fresh' defects, all tissues in
the constructs were bonded to the adjacent cartilage. In the first
study PA70/30 resulted in an overall significantly better repair
tissue than PA55/45, if implanted in a fresh osteochondral defect.
Conspicuously, the PA70/30 scaffolds were surrounded by a large
number of giant cells and phagocytes, suggesting an extensive
ongoing degradation process, which probably inhibits the bone
formation.
Conclusion: Seeding, or seeding and culturing with allogeneic
chondrocytes did not improve cartilage formation in this model.
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MECHANISM OF PAIN REDUCTION BY HYALURONAN
DERIVATIVES (HYLANS)
A Gomis, E Dc la Pena, M Pawlak, R F Schmidt and C Belmonte
Institutode Neurociencias,UniversidadMiguelHernandez-CSIC,
Alicante,Spain.
We explored the possibility that intra-articular hyaluronan solutions
act as elastoviscous filters for the transmission of force to mech-
anosensory channels of pain receptors (nociceptors) and that
this effect depends on the molecular weight of the hyaluronan
solutions.
Methods: Electrical activity of single fibers innervating the intact
knee joint was recorded from fine filaments of the median articular
nerve of anesthetized rats. Mechanical stimulation consisted in
controlled inward and outward rotations of the knee joint within and
outside its normal working range, for 50 severy 5 mm. Solutions of
sodium hyaluronan of different molecular weights (-2000,000 to
-6,000,000) were injected into the joint cavity (0.05 ml). Impulse
discharges evoked by the movements were compared before and
after injection. Also, patch-clamp recordings in the cell-attached
and outside-out configurations were performed from Xenopus
oocytes in Barth's medium (control condition) and exposed to
hylans of different elastoviscosities. For mechanical stimulation
graded suction was applied through the microelectrode.
Results: Hylan G-F 20, a clinically used hyaluronan derivative
(MW -6M), significantly reduced in the course of 1 hour the
number of nerve impulses evoked by movements in the rat joint
pain fibers to about 60 % of the control frequency. No significant
decreases of the mean impulse frequency were obtained with
lower MW «2 M) hyaluronan solutions used therapeutically. In
mechanosensory channels of intact oocytes and of outside out
membrane patches, suction-evoked channel activity was signifi-
cantly reduced in the presence of G-F 20. This attenuating effect
was not observed with non-elastoviscous hyluronan solutions of
low MW.
Conclusion: Mechanosensory channels which are presumably
involved in mechanotransduction have a decreased mechanical
sensitivity in the presence of high MW hyluronan solutions. These
results suggests that the analgesic effect of intra-articular injection
of hylan elastoviscous solutions in animals and arthritic patients is
due to a reduced responsiveness of knee joint pain receptors.
Acknowledgements: Supported by Genzyme Biosurgery, USA.
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PAIN RELIEF IS NOT A CONFOUNDER IN JOINT SPACE
NARROWING ASSESSMENT OF FULL EXTENSION KNEE
RADIOGRAPHS
K Pavelka1, LC Rovati2 , J Gatterova1, 0 Bruyere4 , R Deroisy4,
S Machacek1 , G Giacovel1i2 , C Gonzalez2 , JY Reginster4
llnstituteof Rheumatology,Prague, Czech_Republic,2Rotta
Research Laboratorium,Monza, Italy, llnstituteof Rheumatology,
Prague, Czech Republic,4Bone and CartilageResearch Unit,
Univ. ofLiege, Liege, Belgium
Background: Presence of pain may impair knee full extension in
weight-bearing antero-posterior radiographs using such patient
positioning and view, in osteoarthritis (OA) disease modification
studies.
Objectives: To assess whether improvement in knee pain
improved the fully extended knee position, resulting in an artifac-
tual increase in joint space width (JSW) in two recent trials shOWing
symptom and joint structure modification with glucosamine sulfate
(GS).
Methods: 212 and 202 patients with knee OA (ACR criteria),
respectively (total 414), were randomised to double-blind treat-
ment with oral GS 1500 mg u.i.d. or placebo for 3 years. JSW was
assessed with the aid of a magnifying lens at the narrowest point of
the medial compartment of the tibio-femoral joint, and symptoms
were assessed by the WOMAC index. For the purpose of this
analysis, 3-year completers were selected based on a cut-off of
improvement in the WOMAC pain subscale equal to the mean
improvement observed in the GS group in each study. The average
improvement in WOMAC pain and the mean (ES) change in JSW
were calculated for these patient subsets and compared between
treatment groups.
Results: Data in the combined analysis reported here reflect the
results in each study, that were similar. There were obviously more
patients above the selected pain improvement threshold with GS
(74 vs 56 with placebo, in the two studies combined), but the two
subsets has a similar baseline level of mild to moderate pain and
JSW around 4 mm, similarly to the overall treatment groups.
Notwithstanding a major decrease in WOMAC pain of comparable
size in both patient subsets, -59% with GS vs -51% with placebo
(NS), the placebo patients underwent a definite joint space nar-
rowing (JSN) of -0.23 (0.11) mm that was not observed with GS,
+0.14 (0.06) mm: p=0.005.
Conclusion: Major relief in mild to moderate pain is not a
confounder in the evaluation of JSN on weight-bearing knee
radiographs taken in full extension. The structure modifying effect
of GS is not an artifact of the drug symptomatic activity.
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CARTILAGE DEFECTS, SUBCHONDRAL BONE MARROW
CHANGES, PAIN AND KNEE OSTEOARTHRITIS
MF Sowers, CW Hayes, 0 Jamadar
Universityof Michigan,AnnArbor, MI, USA
Aims: Determine if the presence of subchondral bone marrow
abnormalities (BME) and cartilage defects, would explain the
difference between painful osteoarthritis of the knee (OAK) vs.
painless OAK vs. pain without OAK.
Methods: Magnetic resonance imaging (MRI) with 1.5 T scanner
of four groups of 120 women (30 per group), aged 35-55 years,
were recruited from the Southeast Michigan Osteoarthritis cohort
(1-painful OAK; 2-painless OAK; 3-knee pain without OAK; 4-
neither OAK nor knee pain). OAK was defined by a Kellgren-
Lawrence score of 2 or greater while pain was based on self-
report.
Findings: BME lesions were identified in 56% of all knees. BME
lesions~ were 4 times (95 CI=1.7,8.7) more likely to occur in the
painless OAK group as compared to the group with pain but no
OAK. BME lesions> 1 em were more frequent (OR=5.0, 95 CI=1.4,
10.5) in the painful OAK group vs. all others. While the frequency
of BME lesions was similar in the painless OAK and painful OAK
groups, there were more lesions> 1 em in the painful OAK group.
One-third of knees with full-thickness cartilage defects and 47% of
knees with cartilage defects involving bone had BME > 1 em.
Women with painful OA and full-thickness articular cartilage
defects with adjacent subchondral bone defects were significantly
more likely to have painfUl OAK than other groups.
Conclusion: BME associated with full-thickness cartilage defects
presented consistently with knee pain and is useful in explaining
the difference between painful OAK vs. painless OAK.
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IMMEDIATE EFFECTS OF ADHESIVE TAPE ON PAIN AND
PHYSICAL IMPAIRMENTS IN INDIVIDUALS WITH KNEE
OSTEOARTHRITIS
RS Hinman, KL Bennell, KM Crossley, JM McConnell
Centre for SportsMedicineResearchand Education,University
ofMelbourne, Victoria,Australia
AIM OF STUDY: To evaluate the effects of two knee taping
techniques (therapeutic tape and neutral tape) on pain and
selected parameters of physical function in individuals with symp-
tomatic knee osteoarthritis (OA).
METHODS: Using a within-subjects study design, 12 women and
6 men (mean (SO) age 66.9 (6.5) years) with symptomatic knee
OA (as defined by the American College of Rheumatology) partici-
pated. Each participant was assessed under three testing condi-
tions in random order (determined by balanced Latin square
design): untaped, whilst wearing therapeutic knee tape and whilst
wearing neutral knee tape. Therapeutic tape aimed to realign the
patella and unload the infrapatellar fat pad, whilst neutral tape
aimed to provide cutaneous input only. Physical impairment
measures included: self-selected fast walking speed on a level
surface, Timed Up and Go test, knee joint position sense, isometric
quadriceps strength, electromyographic onset of quadriceps
817
activity during stair descent. step test and postural sway. Severity
of pain experienced during each physical test was measured on a
visual analog scale. Results were analysed statistically using either
a one-way repeated measures analysis of variance or the Fried-
man test. Paired t-tests or the Wilcoxin Signed Ranks test were
used to locate the source of significant differences, using a
Bonferroni adjusted IX of 0.017.
RESULTS: Therapeutic tape significantly reduced pain during
level gait, stair descent, step test and postural sway assessment
when compared to the neutral and untaped conditions (p<0.017).
Tape application had little effect on the physical function par-
ameters investigated, with the exception of the step test, which
was significantly improved by therapeutic tape when compared to
the neutral and untaped conditions (p<0.001).
CONCLUSIONS: Therapeutic knee tape is a simple, inexpensive
self-management strategy that may be used in the conservative
treatment of knee OA. Whilst effective in immediately reducing
pain on activity, it does not appear to have a significant immediate
impact on physical impairments associated with the disease.
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OMERACT-OARSI Initiative: OARSI set of responder criteria
for osteoarthritis (OA) clinical trials revisited
T Pham, 0 van der Heijde, R Altman, J Anderson, N Bellamy,
M Hochberg, L Simon, V Strand, T Woodwortb, M Dougados
RheumatologyB Department, CochinHospital, Paris, France.
Background: The OARSI Standing Committee for Clinical Trials
Response Criteria Initiative had developed 2 sets of responders
criteria permitting to present the results of changes after treatment
in 3 symptomatic domains, i.e.. pain, function and patient's global
assessment, as a single variable for clinical trials (1). For each
domain, a response was defined by both a relative and an absolute
change and with different cut-offs with regard to the drug, the route
of administration and the OA localization.
Objective: To propose a simplified set of responder criteria with
similar cut-off. whatever the drug, the route or the OA localization.
Methods: Data driven approach:Data from clinical randomized
blinded placebo controlled trials were used to evaluate the per-
formances of the two formal scenarios with 2 different databases
("elaboration" versus "revisit") and those of the 4 proposed
simplified scenarios within the "revisit" database. The placebo
effect, active effect, treatment effect, and the sample arm size
needed to obtain the sensitivity and the specificity observed
were evaluated for each of the 6 scenarios. Expert's opinion
approach:Results were presented to the OMERACT expert mem-
bers who selected the most appropriate set of responder criteria.
Results: Data driven approach: 15 studies involving 8164 OA
patients were enrolled in the "revisit" database. The variability
observed in the revisit database with the different sunplified
scenarios was similar to the one observed between the 2 data-
bases (elaboration versus revisit) for the formal scenarios. The
treatment effect and the sample arm size required were similar for
each set of criteria. Expert'sopinionapproach:According to the
experts, these two previous performances are the most important
of an optimal set of responder criteria. Their choice fell on the set
of criteria considering both pain and function as evaluation domain
and requiring an absolute change and a relative change from
baseline to define a response, with similar cut-off whatever the
drug, the route of administration or the OA localization evaluated.
Conclusion: This data driven and expert's opinion approach has
permitted to propose an optimal simplified set of responder criteria
for OA clinical trials.
(I)Dougados M et al.. Osteoarthntis and cartilage, 2000. 8: 395-
403.
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THE OSTEOARTHRITIS INITIATIVE: A PUBLIC-PRIVATE
PARTNERSHIP
Gayle E Lester, Ph.D.
ProjectCoordinator;NationalInstituteofArthritisand
Musculoskeletaland Skin Diseases;NationalInstitutesofHealth;
Bethesda, MD 20892
OA is a major cause of disability and loss of quality of life. There
are few if any current disease modifying drugs for OA. Clinical
Indicators of OA are weak at best and include: pain, disability, joint
space narrowing. Clinical endpoint studies are long and expensive
with currently existing methodologies. Validated biomarkers are
the key to shortening this process and improving decision making
for drug development. In order to develop such biomarkers, we
need a better understanding of the disease: etiology, onset, and
progression.
A population-based longitudinal study of osteoarthritis would
address these research needs and supply opportunities of further
research in OA. It would provide resources to help remove the
barriers that currently exist to moving research forward in the area
of clinical OA. What role can NIH play in facilitating research
advances?
The idea for an Osteoarthritis Initiative was conceived as a means
to create a research resource to aid in the identification and
evaluation of biomarkers as candidates for surrogate endpoints for
OA. The mechanism was the development of a prospective,
natural history cohort to be followed for 4-5 years. Clinical and
imaging data and biospecimens will be collected. This Initiative is a
public- private partnership with intellectual input and planning
carried out by representatives from private industry, academic
centers, government agencies, and private foundations. The finan-
cial support of this initiative will be provided by private industry and
the government through the NIH.
What will result from the OAI? The recruitment of a new cohort,
enriched for "at risk" individuals. The establishment of a public
database that will provide research resources for biomarker vali-
dation in the forms of biological specimens, imaging files and
paired clinical data. This research resource will stimulate basic
research on biomarkers for OA and in turn, facilitate drug develop-
ment through the identification of biomarkers of disease onset and
progression. The long term result of this Initiative will be the
confirmation of biophysical/ radiological, biochemical, genetic, and
phenotypic patterns associated with onset and progression of OA
leading to streamlined clinical trials, and a more thorough under-
standing of the disease and its manifestations in at risk popula-
tions. Such advances will lead to increased development of
disease modifying drugs and treatments and more efficient safety
and efficacy assessments in clinical trials. Positive, interactive
relationships between agencies involved.
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QUANTITATIVE MORPHOLOGICAL ASSESSMENT OF
CARTILAGE IN OA BY MAGNETIC RESONANCE IMAGING
(MRI)
F Eckstein, K-H Engelmeier, M Reiser
InstituteofAnatomyand InstituteofDiagnosticRadiology,
LMU MOnchen, GSF NationalResearch CenterNeuherberg,
Oberschle/Bheim,Germany
Analyses of form-function relationships and disease processes in
human articular cartilage required in vivo assessment of cartilage
morphology and deformational behavior. MR imaging and
advanced digital post-processing techniques have opened novel
possibilities for quantitative analysis of cartilage morphology, struc-
ture, and function in health and disease. The presentation will
review work on three-dimensional post-processing of MR image
data of cartilage and summarize studies on their accuracy and
precision in human joints. Particular focus will be on the validation
of measurements in various stages of OA. We will present norma-
tive values on cartilage volume, thickness, and joint surface areas
in the healthy human knee, and describe the correlation between
different joint surfaces and that with gender, body dimensions, and
age. We will summarizes ongoing work on functional adaptation of
articular cartilage to mechanical loading, analyses of in situ carti-
lage deformation in intact joints in vivo, and the quantitative
evaluation of cartilage tissue loss in osteoarthritis.
Specifically, we will describe dedicated algorithms for image seg-
mentation, reconstruction, and image analysis (thickness, surface
size, surface curvature). We will show that fat-suppressed gradient
echo sequences permit highly accurate analysis of cartilage mor-
phology, both in healthy and severely osteoarthritic joints. Repro-
ducible measurements (CV% =1 to 3 %) can be obtained in most
compartments of the human knee, and also in joints with thinner
cartilage (CV% = 2 to 10 % in the ankle). However, we will show
that the precision is dependent on the specific section orientation
and resolution. Data on the long-term vs. short-term precision of
cartilage volume and thickness measurements will be presented
as well as matching algorithms for analysis of regional/local
changes in cartilage thickness. It will be shown that relatively small
differences in cartilage morphology exist between both limbs of the
same person (-5%), but large differences between individuals
(CV% -20%). Men display only slightly thicker cartilage then
women (-10%), but significantly larger joint surface areas (-25%),
even when accounting for differences in body weight and height.
Weight and height represent relatively poor predictors of cartilage
volume and thickness, but the size of the bone cartilage interface
represents a useful parameter for normalizing cartilage volume
measurements to achieve reasonable T-scores of cartilage loss in
cross-sectional studies. The level of physical exercise does not
appear to account for inter-subject differences in cartilage thick-
ness. The thickness decreases slightly in the elderly, even in the
absence of osteoarthritic cartilage lesions. Moreover, the deforma-
tional behavior of the cartilage decreases with age versus that in
young healthy volunteers.
Application of these techniques to larger cohorts of patients in
epidemiological and clinical studies will further establish the role of
quantitative cartilage imaging in clinical research and in the man-
agement of OA. In particular we will describe how MR-based
techniques can be potentially applied to evaluate SMOADs.
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NEW PERSPECTIVES IN THE MEDICAL MANAGEMENT OF
OSTEOARTHRITIS
Jean-Yves REGINSTER 1-2
Bone and CartilageMetabolismUnit, UniversityofLiege, Liege,
Belgium
WHO CollaboratingCenter for PublicHealth Aspectsof
OsteoarticularDisorders,Dept ofEpidemiologyand Public
Health, Universityof Liege, Liege, Belgium
Until recently, the main aim of pharmacological treatments of
osteoarthritis has been to control the symptoms of the disease. On
the other hand, due to their mechanism of action, specific com-
pounds may not only modify the course of symptoms over long-
term treatment periods, but also favourably affect joint structure
changes and thus the disease progression.
The structure-modifying properties of Chondroitin sulfate (CS)
were assessed in a double-blind, placebo-controlled trial that
included 119 patients with interphalangeal OA. After 3 years, the
group taking 400 mg CS three times daily had significantly fewer
patients with new erosive OA finger joints (8,8 %) compared to the
placebo group (29,4 %). More recently, a dose of 800 mg/day of
chondroitin sulfate, given for a period of 2 years to patients with
primary knee osteoarthritis, prevented the decrease in joint space
width and joint space thickness observed in patients having
received the placebo for the same duration. To test the long-term
effects of Glucosamine sulfate (GS) on the progression of OA joint
structural changes in symptoms of the knee 212 patients with knee
OA were randomly assigned in a double-blind fashion to a continu-
ous treatment with GS (1500 mg once/day) or placebo for 3 years.
Patients treated with placebo had an average joint space narrow-
ing (JSN) of approximatively 0.08 to 0.1 mm/year, while no joint
space narrowing occured in the group treated with glucosamine
sulfate. These results were later confirmed by another double-
blind, placebo-controlled study, performed in 202 patients with
knee OA. In the glucosamine group, the minimum joint space width
of the tibio-femoral joint increased by 0.02 mm after 3 years while
it decreases by 0.19 mm in the placebo group. In a three-year,
randomized, double-blind, placebo-controlled study, 507 patients
with severe to moderate hip osteoarthritis were randomized to
receive either diacerein, 50 mg twice daily or identical placebo. At
the end of the trial, 62.7 % of the placebo and 53.7 % of the
diacerein treated patients (p = 0.037) had a radiological progres-
sion defined as a reduction in the joint space width of at least
0.5 mm. Within the valid completers population (n=269), the
annual joint space narrowing rate was significantly lower in those
receiving placebo (0.018 mm/year versus 0.023 mm/year;
p=0.04;2).
There is now a convergent body of evidence that several sub-
stances acting either through a synthesis of matrix constituants or
through an inhibition of catabolic mediators and processus can
significantly interact with the progression of osteoarthritis. The
most conclusive evidence stands with glucosamine sulfate.
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ISOMERIZED AGGRECAN FRAGMENTS ARE RELEASED
DURING CARTILAGE DEGRADATION AND CAN BE
MEASURED IN SERUM
S Christgau1 , PAC Cloos1 , C Christiansen2 , D Bang Henriksen1.
1NordicBioscienceAlS, Herlev, Denmark;2Center for Clinical
and BasicResearch, Ballerup, Denmark.
Isomerization of asparaginyl and aspartyl residues is a posttrans-
lational process occurring spontaneously at susceptible sites in
long-lived proteins. In tissues with low turnover rate such as
cartilage, significant amounts of age-modified proteins may accu-
mulate.
Our aim was to characterize isomerization prone aspartyl/
asparaginyl residues (iso-D) in non-collagenous cartilage proteins.
A human cartilage sample obtained from a recently deceased
human male donor (age 60 years) was extracted with 4 M
Guanidinium-HCI and subsequently centrifuged at 27,000 x g.
Aliquots of the supernatant were subsequently reduced and
digested with trypsin. Tryptic digests were subjected to size-
exclusion chromatography (SEC) and further purification using
reverse phase HPLC. Eluents were collected in fractions and
measured in an enzyme-assay employing the enzyme L-Iso-
Aspartate Methyl Transferase (IAMT, EC 2.1.1.77) for detection of
iso-D containing protein fragments. Fractions containing iso-D
sites as identified with the IAMT enzyme were purified to hom-
ogeneity and subsequently subjected to amino acid sequencing
and mass spectrometry to identify the cartilage protein fragments
containing iso-D modifications.
Iso-D sites were identified in aggrecan as well as other cartilage
matrix proteins. Synthetic peptides representing several of these
sites were synthesized and used to generate immunoassays, for
measurement of iso-D containing aggrecan fragments in circula-
tion. Fragments of aggrecan containing an isomerized form of the
epitope GRVRV-isoD-SAY were found in circulation. The levels of
such fragments were elevated in OA and RA patients suggesting
that they may provide a novel biochemical marker of cartilage
catabolism.
Further studies are needed to assess the functional significance of
these spontaneous posttranslational modifications. The clinical
potential of isomerized aggrecan fragments to reflect cartilage
degradation in arthritis and other conditions involving elevated joint
tissue metabolism is currently being investigated.
